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Summary
Rheumatoid arthritis (RA) is, for the time being, an incurable disorder in which
the irreversible damage of joints frequently leads to disability. The major patho-
logic phenomena in RA are the inflammation of the synovial tissue, the autoim-
mune reaction and synovial hyperplasia resulting in the destruction of cartilage.
The autoimmune cells are believed to be central to RA. Moreover, autoantibod-
ies directed at self can be detected even years before the onset of symptoms of
the disease. Therefore, autoantibodies are suggested to play a role in the patho-
genesis of the disease including its early stages. Moreover, some of them serve
as diagnostic markers, disease progression markers, or define subsets of RA pa-
tients. Since the identification of novel autoantibodies could be important for
understanding specific disease mechanisms, in the first part of the thesis I focused
on the characterisation of novel autoantibodies in RA. On the other hand, RA
synovial fibroblasts (RASF), which are the resident cells of the hyperplastic syn-
ovium in RA, are thought to be effector cells driving the destruction of cartilage in
RA. They invade into cartilage and destroy it by releasing considerable quantities
of matrix degrading enzymes such as matrix metalloproteinases (MMPs). More-
over, they overexpress small ubiquitin-like modifier (SUMO)-1 and have decreased
levels of SUMO specific protease SENP1 which renders them resistant to induced
cell death (apoptosis). RASF have recently been shown to have aberrations in the
epigenetic code. The epigenetic code is responsible for turning on the genes which
are specific for a given cell type (e.g. for fibroblasts of the synovium) and turning
off those which should not be active in any particular type of cell. Acetylation
of histones is one of the epigenetic modifications responsible for the arrangement
of a proper epigenetic code. The field of epigenetics is relatively new and there-
fore there is not much known about epigenetic modifications in RA. Since histone
acetylation modulates gene activity, in the second part of the thesis I hypothesised
that the acetylation status could be altered in RASF which might result in the
intrinsic overexpression of MMP-1. Furthermore I demonstrated a link between
the downregulated SENP1 and the status of histone acetylation in RA.
In the first part of this work, a novel type of autoantibodies has been identified in
RA anti-serpin E2 autoantibodies. Serpin E2 antigen was overexpressed in RA
compared to OA synovial tissues. Anti-serpin E2 autoantibodies were detected at
elevated levels in RA synovial fluids comparing to control patients with osteoarthri-
tis. Most importantly, anti-serpin E2 autoantibodies were shown to have blocking
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properties and therefore repressing the function of serpin E2. Since serpin E2 is
a natural inhibitor of several serine proteases involved in the pathogenesis of RA,
anti-serpin E2 blocking antibodies present in RA could possibly play a functional
role in the pathogenesis of the disease by the hyper-activation of urokinase and
the plasmin system in RA. However, subsequent studies have shown that these
antibodies are not specific for RA and occur also in a certain number of normal
appearing individuals.
In the second part of my work it has been demonstrated that in RASF the epige-
netic code of MMP-1 was altered. In the promoter of MMP-1 the acetylation of
histones was increased, which contributed to the intrinsic overexpression of MMP-
1. This was at least partially due to low levels of SENP1 in RASF since the
overexpression of SENP1 re-established the proper histone acetylation pattern in
the MMP-1 promoter as well as the expression of MMP-1. For this regulation
SENP1 required a histone deacetylating enzyme histone deacetylase (HDAC) 4,
which decreased the acetylation of histones in the promoter of MMP-1. Most in-
terestingly, this had a functional consequence, since RASF overexpressing SENP1
were significantly less invasive comparing to control RASF.
In summary, there is evidence that anti-serpin E2 autoantibodies are present at
increased levels in a certain number of RA patients and block the protective func-
tion of serpin E2. To my knowledge they are the first autoantibodies shown to
have a distinct function which might be related to the regulation of the proteolytic
plasmin system. On the other hand, there is evidence that aberrant expression of
SENP1 leads to modifications in the epigenetic code in RASF leading to the over-
production of MMP-1 as well as to an increased invasiveness of the cells. Therefore,
re-establishing the expression of SENP1 in RASF could be a promising approach
for the therapy in RA.
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Zusammenfassung
Die Rheumatoide Arthritis ist eine systemische Auoimmunerkrankung. Haupt-
charkteristikum dieser Erkrankung ist die progressive Zersto¨rung der Gelenke.
Meist sind Hand-, Finger, Zehen und Kniegelenke betroffen, in der Regel sym-
metrisch. Diese Gelenkerkrankung ist bis heute nicht heilbar. Die anhaltende
Entzu¨ndung der Gelenke resultiert in einer Autoimmunreaktion, bei der Knorpel-
und Knochenstrukturen angegriffen und zersto¨rt werden. Mit fortschreitender
Erkrankungszeit kommt es zur vo¨lligen Zersto¨rung der betroffenen Gelenke und
damit zur Bewegungsunfa¨higkeit. Die Autoimmunreaktion spielt eine zentrale
Rolle in der Pathogenese der Erkrankung. Ku¨rzlich konnte gezeigt werden, dass
bereits Jahre vor Ausbruch der Erkrankung Autoantiko¨rper bei diesen Personen
nachgewiesen werden ko¨nnen. Autoantiko¨rper spielen auch bei der klinischen Di-
agnose der Erkrankung eine grosse Rolle. Mittlerweile gibt es bereits U¨berlegungen
wonach die Erkrankung anhand der Autoantiko¨rper-Muster in neue Sub-Gruppen
eingeteilt werden ko¨nnten. Von der Identifizierung neuer Autoantiko¨rper bei der
Rheuamtoiden Artrhitis verspricht man sich die Aufkla¨rung weiterer Pathomech-
anismen und/oder zusa¨tzliche diagnostische Marker.
Im ersten Teil meiner Arbeit konzentriere ich mich auf die Identifizierung und
Charakterisierung neuer, bisher unbekannter Auto-Antiko¨rper in dieser Erkrankung.
Dabei untersuchten wir das Auftreten neuer Autoantiko¨rper zum einen systemisch
in Seren und zum anderen lokal das Auftreten von Autoantiko¨rper in der Syn-
ovialflu¨ssigkeiten betroffener Gelenke von Patienten mit Rheumatoider Arthritis.
Im zweiten Teil meiner Arbeit fokussiere ich mich auf die Bindegewebszelle, den
synovialen Fibroblasten (RASF) in den betroffenen Gelenken dieser Patienten.
Diese Zellen galten lange Zeit als unbeteiligte Strukturzelle der Bindegewebskapsel.
Mittlerweile weiss man, dass diese Zellen die eigentliche Effektorzellen sind, die
nach Aktivierung Knorpel- und Knochenzersetzenden Enzyme wie Matrix-Metallopro-
teinasen (MMPs) freisetzen. Diese als tumora¨hnliche beschriebene Zellen zeich-
nen sich unter Anderem durch eine gesteigerte Apoptoseresistenz und damit einer
Vermehrung dieser Zellen im betroffenen Gelenk aus. Diese Apoptose-Resistenz
wird vermittelt durch eine U¨berexpression von Ubiquitin-like Modifier (SUMO)-
1 einhergehend mit einer verringerten Expression des Gegenspielers der SUMO
spezifischen Protease SENP-1. Da Genexpression reguliert werden kann durch
epigeneische Modifikationen, haben wir hier untersucht, ob diese Vera¨nderungen
zum aktivierten and aggressiven Pha¨notype dieser Zellen beitragen. Dabei habe
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ich mich auf den Einfluss der Acetylierung auf die Expression der Matrixmetallo-
proteinase 1 (MMP-1) und SENP-1 in synovialen Fibroblasten von Patienten mit
Rheumatoider Arthritis konzentriert.
In ersten Teil meiner Arbeit zeige ich dass bei Patienten mit Rheumatoider Arthri-
tis Autoantiko¨rper gegen eine Serin-Protease Serpin-E2 nachweisbar sind. Mittels
Immunhistochemie konnten wir das Antigen SerpinE2 in ho¨heren Mengen in der
Synovialmembran von Patienten mit RA nachweisen im Vergleich zu Patienten
mit Osteoarthritis, einer nicht-entzu¨ndlichen degenerativen Erkrankung der Ge-
lenke, die in der Regel zu Vergleichzwecken verwendet wird. In Serum und in
Synovialfu¨ssigkeiten fanden wir erho¨hte Level von Autoantiko¨rper gegen SerpinE2
in den von uns untersuchen Proben. Neu ist, dass wir das Auftreten dieser Autoan-
tiko¨rper mit einem funktionellen Aspekt in Verbindung bringen konnten. Wir kon-
nten zeigen, dass das Auftreten dieser Autoantiko¨rper, abha¨ngig von der Menge,
auch die Funktion der Serinprotease SerpinE2 hemmt. Mo¨glicherweise hemmt
das vermehrte Auftreten dieser Autoantiko¨rper bei Patienten mit Rheumatoider
Arthritis die Serinprotease SerpinE2 in ihrer Funktion und fu¨hrt so zu einer Hy-
peraktivierung derer Zielproteine Urokinase und/oder das Plasmin System. Es
muss bemerkt werden, dass spa¨tere Studien gezeigt haben, dass diese Antiko¨rper
nicht spezifisch fu¨r RA sind und auch bei einer bestimmten Anzahl von gesund
erscheinenden Personen vorkommt.
Im zweiten Teil meiner Arbeit konnte ich aufzeigen, dass synovial Fibroblasten
von Patienten mit Rheumatoid Arthritis epigenetische Modifikationen bezu¨glich
ihrer Acetlierungsmuster, am Promotor der Gens fu¨r MMP-1 aufweisen. Eine
Hyperacetylierung des Promotors dieser Matrixmetalloproteinase fu¨hrt zu deren
versta¨rkten Expression und tra¨gt deshalb zum aktivierten und aggressiven Pha¨no-
type der Zellen bei. Eine Aufregulierung von SENP-1 in diesen Zellen reduzierte die
Acetylierung durch die Aktivierung von Histondeacetylase 4 (HDAC4) im MMP-
1 Promotor und somit dessen Expression. Auch in einem funktionellen in vitro
Invasiontest konnten wir zeigen, dass eine Aufregulierung von SENP-1 zu einem
signifikant weniger invasiven Pha¨notyp dieser Zellen fu¨hrt.
Zusammenfassend konnten wir erho¨hte Level von Autoantiko¨rper gegen SerpinE2
bei Patienten mir Rheumatoid Arthritis aufzeigen, die daru¨ber hinaus auch noch
eine funktionelle Rolle in der Pathogenese dieser Erkrankung haben, indem sie
die Schutzfunktion der Serinprotease SerpinE2 blockieren. Das ist meinem Wis-
sen nach die erste Beschreibung einer Funktion eines Autoantiko¨rpers. Weiterhin
konnten wir zeigen, dass die Aufregulierung der Expresssionslevel von SENP-1 den
aggressiven und invasiven Pha¨notyp der synovialen Fibroblasten von Patienten mir
Rheumatoider Arthritis aufhebt, da so die apoptoseresistenz dieser Zellen aufge-
hoben wird und die u¨berma¨ssige Expression von MMP-1 gehemmt werden kann.
Dies ko¨nnte ein neuer vielversprechender Ansatz fu¨r neue Therapien sein.
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1 Introduction
1.1 Background
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease of which
the main characteristic is joint destruction [1]. Since the changes in joints lead to
the loss of function, RA frequently results in disability and is accompanied with
chronic pain. RA is also the most common inflammatory rheumatic disease and
therefore the economical burden is high. Furthermore, even though there has been
a major brake through in the treatment of RA in the recent years, the high cost
of the treatment as well as a subgroup of non-responders remain an issue. There
is, therefore, a priority to identify novel targets for treatment by studying aber-
rantly inhibited or activated pathways in RA. One of the main features of RA
is the presence of high affinity autoantibodies. Certain autoantigens have been
implied to contribute to the induction and maintenance of inflammatory reactions
against the host tissue(s) [2, 3]. Therefore, the identification of novel autoantigens
in RA appears to be very important for a better understanding of specific disease
mechanisms. SEREX (Serological Analysis of Recombinant cDNA Expression Li-
braries), an established tool widely used in screening for autoantigens has been
successfully employed to identify autoantibodies associated with different diseases
in particular in cancer research [4, 5]. Nevertheless, never before has it been used
in the context of RA. In my thesis, using the SEREX technique I identified novel
autoantibodies against serine protease inhibitor serpin E2. I could further show
that the specific autoantibodies against serpin E2 blocked its inhibitory activity
towards serine proteases and therefore they might facilitate the joint destruction in
RA. To my knowledge, this study is the first to show a distinct functional property
of an autoantibody that might be related to the pathogenesis of RA. On the other
hand, more and more evidence suggest the importance of activated RA synovial
1
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fibroblasts (RASF) in the pathogenesis of RA. Therefore, studying aberrations in
these distinctive cells appears highly promising. Moreover, the growing knowledge
in the new field of epigenetics gives us the opportunity to translate it into the
context of RASF and the disease itself. The group of Prof. Steffen Gay, which
is one of the leading groups in the field of RA in Europe and one of few with a
high interest in the novel field of epigenetics of RA, provided therefore the best
circumstances for me to perform my PhD. In the second part of the present work
I identified a novel aberration in the epigenetic code in RASF involving increased
acetylation of histones in the promoter of matrix metalloproteinase (MMP) -1
leading to its overexpression. This phenomenon was linked to a downregulation
of SUMO/sentrin specific protease SENP-1. These results provide two distinct
pathways as potential targets for the regulation of MMP-1, of which increased
expression contributes considerably to the destruction of cartilage in RA.
1.2 Rheumatoid Arthritis
1.2.1 Epidemiology
RA occurs worldwide and affects about 1 percent of the Western Europeans pop-
ulation being the most common of the inflammatory joint diseases. Women have
3 times increased risk of RA compared to men. Urban living individuals have
increased risk of RA compared with those living in the rural areas [6]. The disease
is heritable to a low extent, since the concordance between the monozygotic twins
is 32%. The disease onset is most commonly observed in individuals between 30
and 60 years old.
1.2.2 Clinical aspects
Due to synovitis, the main symptoms of RA are swelling of multiple joints, which
become tender, warm and their stiffness cause difficulties to move [7]. Usually, RA
affects multiple joints of the hands, feet and cervical spine but also can involve
larger joints like the wrist, elbow, shoulder or knee. As the disease progresses, it
can also involve other organs such as skin, where the rheumatic nodules can be
2
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formed, and lungs. Moreover, in the severe course of RA, vasculitis can also be
observed. Patients with RA are more prone to atherosclerosis and have generally
an increased risk of cardiovascular events like heart attack and stroke [8]. The
extra-articular symptoms occur in about 15% of patients. Other symptoms are
the morning stiffness, in or around the joint, which lasts for more then an hour.
Radiographic changes can be identified as deterioration of cartilage and erosions
of bone. Patients with RA generally have increased levels of rheumatoid factor
(RF) and pro-inflammatory cytokines [9, 10]. However, the disease might start long
before the onset of symptoms, since increased levels of pro-inflammatory cytokines
and some autoantigens might be detected in sera even 10 years before the disease
is diagnosed [11, 12, 13, 14]. The patients with RA are classified according to the
ACR criteria [15].
1.2.3 Pathophysiology
The pathogenic phenomena in RA occur mainly in the synovial tissues. The
main function of the synovial tissue in a healthy joint is supplying synovial fluid
which lubricates the cartilage and minimizes the friction of the bones. In RA, the
synovial tissue overgrows as a result of infiltration by immune cells and increased
survival rate of the resident synovial cells (Figure 1). Activation of the infiltrating
immune cells leads to a self-directed attack localized to joints and is followed
by joint inflammation (arthritis). Activation of resident synovial cells parallels
the inflammation and results in an aggressive invasion of synovial fibroblasts and
macrophages into cartilage and bone leading to their damage [16].
RA is characterized by the thickening of the lining layer of the synovium in the
affected joints, the infiltration of the synovial tissue with inflammatory cells such
as T and B cells and destruction of cartilage and bone by activated RA synovial
fibroblasts (RASF) and osteoclasts [17, 18]. Activation of cells of the immune
system leads to an increase in inflammation and production of autoantibodies.
Activation of RASF leads to an increased production of pro-inflammatory cy-
tokines and chemokines that in turn attract more inflammatory cells to the in-
volved joints [19]. Moreover, RASF excessively express matrix degrading enzymes
such as MMPs which leads to irreversible destruction of joint structures [17]. Fur-
3
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Figure 1.1: Scheme showing a normal joint (A) and RA joint where the hyperplas-
tic synovium invades and damages the cartilage and bone (B).
thermore, RASF have been shown to be resistant to apoptosis, which in turn
leads to their accumulation in the synovial tissue and contributes to the activated
phenotype of RASF [20]. Therefore, in RA several pathologic phenomena occur
simultaneously, namely systemic chronic inflammation, autoimmunity, destruction
of cartilage and bone and hyperplasia of the synovium.
1.2.4 Treatment of RA
Currently, a wide range of therapies is available for the treatment of RA. This
includes analgesics, such as acetaminophen and opioids, anti-inflammatory drugs,
such as glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs) that have
both analgesic and anti-inflammatory properties and disease-modifying antirheumatic
4
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drugs (DMARDs) which have complex properties [21]. Should these treatments
prove ineffective, a new class of drugs, biological-response modifiers so called bio-
logicals are of choice. Biologicals include Rituximab, anti-CD20 antibodies, which
is a B cells deprivation agent, tumor necrosis factor α (TNF-α) targeting ther-
apies including Infliximab and Adalimumab, anti-TNF-α antibodies, as well as
Etanercept, a soluble receptor for TNF-α, a recombinant inhibitor of interleukin
(IL)-1 (Anakinra), a recombinant fusion protein comprising the extracellular do-
main of human cytotoxic T-lymphocyte antigen (CTLA)-4 and a fragment of the
Fc domain of the human immunoglobulin (ig)G1 (Abatacept). Recently, a block-
ing antibody for IL-6 receptor (Tocilizumab) has been accepted for the treatment
of RA. Biologicals are powerful drugs for the majority of patients. However, since
not all patients respond to these therapies and there is no cure yet, research has
focused on the cells at the site of joint destruction. More attention is now paid,
for example, on targeting the bone resorbing osteoclasts [18, 22]. Surprisingly,
no interest was raised so far on the notion that, next to the development of au-
toimmunity and activation of the cytokine driven pathway of joint destruction, a
cytokine-independent pathway driven by intrinsically activated RASF is another
important part in the pathogenesis of RA [23, 24]. The epigenetic modulations
have been proposed to be partially responsible for the intrinsic activation of RASF
[25].
1.2.5 Epigenetics and RA
The term epigenetics defines modifications in the genome, inheritable over cell
generations but not involving the base pair sequence of the DNA. Epigenetic mod-
ulations include DNA methylation and histone modifications such as acetylation,
methylation, phosphorylation, ribosylation, ubiquitination and sumoylation (Fig-
ure 2).
So far several epigenetic abnormalities have been described in cancer transformed
cells. Recent studies on epigenetics, including DNA methylation and modulations
of histone acetylation have also contributed to a better understanding of the patho-
genesis of RA. The first report on aberrations in the epigenetic code in RA was
published already in 1990 [27]. The authors showed that the DNA in T cells of RA
5
CHAPTER 1. INTRODUCTION
Ac Ac 
Ac Ac 
Ac 
Ac 
Ac 
Ac 
Ac 
Ac 
Ac 
Ac 
Pol III 
Ub 
Ub 
Ub 
Ub 
SUMO 
Met 
Met 
Figure 1.2: Epigenetic modulations of the chromatin. The global hypomethyla-
tion of the DNA in RA leads to an increase in gene expression. Hy-
peracetylation of histones in specific promoter sites renders the DNA
region accessible for the transcription machinery. MicroRNA encoded
by the DNA silences specific genes in a posttranscriptional manner.
Other modifications of histones are indicated, such as sumoylation,
ubiquitination, methylation and phosphorylation. Methylated cyto-
sine in DNA is shown as filled and nonmethylated as open circles. The
modifications of histone tails are indicated as follows: SUMO sumoy-
lation, Ub ubiquitination, Ac acetylation, P phosphorylation, Me
methylation [26].
patients is hypomethylated. Few years later, RASF have been shown to be intrin-
sically activated and resemble tumor-like cells in some aspects [17]. However, since
RASF do not proliferate extensively they are referred to as cells with an activated
phenotype [19]. It needs to be shown in the future that the epigenetic changes in
the SF could lead to this activated phenotype of RASF.
6
1.2. RHEUMATOID ARTHRITIS
DNA methylation in RA
DNA methylation in gene promoters containing CpG islands takes place on cy-
tosines of the CpGs, and is connected to a decreased transcription of genes, since
transcription factors generally can not bind to promoters containing methylated
CpG islands. In this manner genes in heterochromatin are silenced. Recent in-
vestigations in our group have shown that RASF have decreased levels of global
DNA methylation [25], which leads to an increased expression of cell activating
genes and could possibly stimulate the innate immune response via TLR-9. It
was reported that the transcription of the retrotransposable element LINE-1 is
reactivated in RA synovial tissue due to hypomethylation of CpG islands in its
promoter [28]. A single unmethylated CpG in a promoter of IL-6 in monocytes
was reported rendering the expression of IL-6 more inducible by LPS stimulation
[29]. On the contrary, the CpG island in the promoter of death receptor 3 (DR3),
a member of the apoptosis-inducing Fas gene family, was shown to be specifically
methylated in synovial cells from patients with RA and the expression of DR3 was
accordingly downregulated [30]. The authors concluded that the downregulation
of DR3 could play a role in the resistance to apoptosis in RA synovial cells. This
finding resembles certain aspects observed in malignant cells where in the stage of
global hypomethylation, methylation of specific promoters, for example in tumor
suppressor genes occurs.
Histone acetylation in RA
Acetylation of histones H3 and H4 in the nucleosomes of gene promoters is related
to the activation of gene expression [31, 32]. This fact is thought to be due to bind-
ing of an acetyl group to lysine residue in histones that abolishes the positive charge
on the lysine and thus loosens the tight interaction between the positively charged
nucleosome and negatively charged DNA. Therefore, the DNA becomes accessible
for the transcription machinery. The status of histone acetylation depends on the
activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs).
It has been described by Huber et al. that in RA synovial tissues the balance of
HAT/HDAC activity is strongly shifted towards histone acetylation [33]. Specif-
ically, a downregulation of HDAC1 and 2 in the synovium of patients with RA
7
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has been shown. In other studies, it has been observed that the HDAC inhibitor
FK228 inhibits joint swelling, synovial inflammation and joint destruction in mice
through the induction of p16INK4a and the upregulation of p21(WAF1/Cip1) [34].
Furthermore FK228 was recently described to suppress the production of VEGF
in vivo and to block angiogenesis in synovial tissue in collagen-antibody-induced
arthritis [35]. Another HDAC inhibitor, trichostatin A (TSA), was shown to induce
cell cycle arrest and apoptosis in RASF and to be particularly effective in combi-
nation with ultrasound treatment [36]. TSA was also shown to sensitise RASF to
TRAIL-induced apoptosis, however in this study TSA had no effect on apoptosis
when used in the absence of TRAIL [37]. The fact that the inhibition of HDACs,
which are already less active in RA, is beneficial suggests that HDACs might be
misplaced in the subcellular compartments, for example being localised aberrantly
to specific promoter sites, and thereby contributing further to the pathogenesis of
RA. Therefore, it might be considered whether inhibition or rather redirection to
a proper localization of HDACs is feasible for the treatment of RA. In 2006 an
interesting study was published comparing gene expression patterns in immortal-
ized B cells from RA patients and from their healthy monozygotic twin siblings
[38]. They could compare modulated gene expression in a setting of no genetically
diverse background. It needs, however, to be investigated whether some of this
modulation could be attributed to epigenetic differences of investigated twins.
MicroRNA in RA
Next to epigenetic modifiers, microRNAs (miRNA) are a recently recognized class
of modulators of gene expression [39]. MicroRNA are small non-coding single-
stranded RNA molecules that downregulate gene expression on the posttranscrip-
tional level. The expression pattern of miRNA has been suggested to be altered in
RA [40]. Indeed, expression of miR-155 and miR-146a was found to be higher in
RASF than in osteoarthritis (OA) SF [41, 42]. Moreover, the expression of miR-
155 was further enhanced by TNF-α, IL-1β, and the ligands of TLR-2, -3 and -4.
Interestingly, the expression of miR-155 in RASF had a repressive effect on the
expression of MMP-1 and MMP-3, suggesting an induction of counter regulatory
mechanisms in the vicious circle of inflammation and destruction. However, in an-
8
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other study, it has been proposed that miR-146a, even tough expressed at higher
levels in RA, is not able to perform its function as a negative regulator for the
expression of TRAF-6 and IRAK-1, two molecules involved into the pathway of
TNF-α synthesis [43]. Most interestingly, microparticles, which are small vesicles
released from activated or dying cells and present abundantly in the synovial fluid
of patients with RA [44], also contain miRNA [41, 45]. These observations sup-
port the notion that microparticles are intra-cellular mediators of inflammation
and entail the activation of synovial cells even more interesting [46].
1.3 Focus of the thesis
The inflammation of the RA synovial tissue, the autoimmune reaction, synovial
hyperplasia and the destruction of cartilage are the major pathologic phenomena
in RA. In the present work I addressed the following problems: 1) In the aspect
of autoimmunity: to identify novel autoantibodies and to study their functional
role; 2) In the aspect of cartilage degradation: to study the involvement of the
acetylation of histones in the regulation of the expression of matrix degrading
enzyme MMP-1. 3) Furthermore I studied the link between the expression of
MMP-1 and the SUMOylation pathway, which is known to be responsible for the
increased resistance of RASF to apoptosis (Figure 3).
1.3.1 Inflammation/Autoimmunity in RA
Even though it is known that the persistent activation of the immune system in
RA leads to autoimmunity [47], the trigger activating the immune response re-
mains unidentified and the pathogenesis of the disease is still not clear. It was
suggested that some infectious agents could be cross-reactive with host proteins
and by molecular mimicry could trigger the immune response against self epi-
topes [48]. Another hypothesis grants that the autoimmunity in RA results from
pathologic selection of self-reactive cells of the adaptive immune system [49]. The
autoreactive T and B cells are though to escape the negative selection and subse-
quent deletion. Self-reactive leukocytes infiltrate and accumulate in a chronically
inflamed RA joint [50]. This is believed to be due to constant delivery of survival
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Figure 1.3: Pathologic phenomena in RA. Inflammation, synovial hyperplasia and
destruction of cartilage are the major characteristics of RA. The topics
addressed in the present thesis are marked in red. Figure modified from
[23].
factors by synovial resident cells as well as to a prolonged and disordered reso-
lution phase of inflammatory response. Activated autoreactive B cells produce
autoantibodies. The prevalence and a plausible role of autoantibodies in RA is
of high interest, since they appear very early in the disease, some even before the
onset of symptoms, they partly correlate with the erosions and they can be spe-
cific for the disease [12, 14, 51]. Most of the recently developed treatments used
in RA target the adaptive immunity. Treatments focusing on B-cells proved to be
successful, however only to a limited extent [52, 53, 54]. Targeting CD4 molecule
on T-cells was inefficient in clinical trials [55]. Targeting TNF-α, which is thought
to stop leukocyte migration and accumulation in the synovium, brought the most
10
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effect, however the ACR70 score is reached by only 60% of the treated patients
[50, 56, 57].
RA and the innate immune system
The role of the innate immunity is the non-specific recognition of pathogens. The
innate immune system constitutes the first defence against microbial particles such
as viruses or bacteria, by which it is activated via pathogen associated molecular
patterns (PAMPs) ligating to pattern recognition receptors (PRRs). Activation
might also occur by other stress factors such as heat, fractures, necrosis, apoptosis,
hypoxia or carcinogenesis via diverse molecules expressed on stressed, injured,
infected, or transformed human cells that also act as PAMPs [58, 59, 60]. The
role of innate immunity in the organism is the identification of foreign substances
and their removal by phagocytosis or production of nitric oxide (NO) and the
recruitment of immune cells to sites of infection or inflammation by producing
cytokines. Moreover, the function of the innate immune system is the activation of
complement cascade and of the adaptive immune system by antigen presentation.
The cells of the innate immune system are equipped with PRRs to be ready for
an immediate response to an offensive event. In this regard, it is interesting that
synovial fibroblasts, especially when derived from RA and other inflammatory
conditions, express on their surface a range of Toll like receptor molecules (TLRs)
belonging to the group of membrane associated PRRs [61, 62]. These cells have
therefore the ability to react immediately or within few hours to a wide range of
appearing pathogens but also to react to interactions with human cells expressing
TLR ligands and induce an immune response. Since RASF express increased
levels of TLR2, 3 and 4, they are more prone to activation by diverse TLR ligands
when compared to OASF [61, 63] (including endogenous ligands). Thus, it could
be hypothesised that RASF function as sensors of danger and can be activated
even in the preclinical phase of RA which could lead to the initiation and early
perpetuation of the disease. Furthermore, binding of endogenous ligands to TLRs
could lead to a constant activation of RASF and maintenance of their pathogenic
phenotype.
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Adaptive immunity in RA
Infiltration of leukocytes to RA synovium The adaptive immune system com-
poses of lymphocytes - specialized immune cells that recognize specifically a patho-
genic epitope and upon this recognition they proliferate proliferate resulting in
multiple copies of a single specific cell clone [64]. Then, activated B cells differen-
tiate to plasma cells and produce immunoglobulins (antibodies) binding specifically
the corresponding antigen. The antigen-antibody complexes activate the comple-
ment system and can be cleared by phagocytosis via Fc receptors expressed on
macrophages [65]. T cells specific for the antigen can stimulate a B cell response
(T helper; CD4+) or directly kill the pathogen by releasing the cytotoxins perforin
and granzymes (T cytotoxic; CD8+) [66]. Whereas helper T 1 (Th1) cells are in-
volved in cellular immunity against intracellular bacteria and viruses by expression
of INF-γ and IL-2, Th2 cells mediate the humoral response to parasitic infection
and are characterised by the production of IL-4. Th17 cells play a critical role in
host defence against extracellular pathogens, particularly those colonizing exposed
surfaces like skin, the mucosa of the airways or lining of the intestines. They are
the major source of IL-17 and induce the production of chemokine gradient lead-
ing to recruitment of the cells of the innate immunity [67]. Another subset of T
cells, T regulatory cells (Treg; CD4+. CD25+, Foxp3+) are responsible for limit-
ing the immune response and for immune tolerance to self antigens and therefore
they constitute a defense system against self directed attack of the immune system
[68]. The effector cytokine of Treg cells is anti-inflammatory IL-10. However, in
autoimmune disorders, such as RA, the cells of the adaptive immunity recognize
self antigens and propagate a self directed autoimmune reaction. In RA, leuko-
cytes are recruited to the synovial tissue by a sequence of interactions between
specific receptors expressed on their surface and correspondent ligands present on
the surface of endothelial cells in the area of inflamed synovium or chemokines re-
leased from the surrounding cells into the blood stream [69]. Following recruitment
to RA synovium, leukocytes find supportive environment for their survival, since
activated RASF and macrophages produce anti-apoptotic factors, such as type I
interferons [70]. This conditions lead to T-cell survival, where T-cells have high
levels of anti-apoptotic Bcl-XL and low levels of pro-apoptotic Bcl-2 [71]. Nev-
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ertheless infiltrated T-cells in RA synovium stay in a state of anergy and do not
proliferate. Resident cells of the RA synovium actively retain infiltrating immune
cells, not only by producing survival factors, but also factors promoting transition
of the phenotype of the leukocytes from migratory to stationary. This transition
occurs by changing the pattern of adhesion molecules and chemokine receptors
expressed on the surface of leukocytes. TGF-β derived from RASF is responsible
for up-regulation of CXCR4 expression on synovial T cells [72]. Moreover, the
ligand for CXCR4, SDF-1 is produced by synovial endothelial cells and the lig-
ation of SDF-1 promotes adhesion of T cells to adhesion molecules ICAM-1 and
fibronectin. Chemokines SDF-1 and BCA-1 which are known to play a role in
the lymphoid organogenesis are present at high levels in the RA synovium where
they promote B-cell attraction, retention and the formation of germinal centres like
structures [73]. These structures are ectopic lymphoid micro-aggregates formed by
accumulating lymphocytes [74]. The aggregates are characterized by a secondary
lymphoid organ-like architecture, with a central area enrichment of B cells which
is surrounded by a T cell peripheral area. Furthermore, these germinal center-
like structures have centrally located follicular dendritic cell network and at the
edges of the follicles terminally differentiated plasma cells producing autoantibod-
ies. They also develop a specialized vascular apparatus and are characterized by
the in situ expression of secondary lymphoid organ chemokines such as CXCL13.
While CD4 positive T cells are mostly present in these follicular aggregates, CD8
T cells are found mostly in the synovial fluid. The contact of infiltrating T cells
with resident macrophages and RASF in the in the synovial tissue stimulates the
two latter to produce TNF-α, IL-1β and other pro-inflammatory cytokines [75].
Thus TNF-α is found at increased levels in RA joint. It was reported that also
TNF-α has a role in the establishment of lymphoid tissue [76]. Another factor that
promotes the retention of T cells in tissue is recognition of an antigen in general,
and in RA synovium, an auto-antigen in particular.
Recognition of auto-antigens In RA, the tolerance of the immune system to-
wards self molecules is broken. It is speculated that infection of susceptible individ-
uals could lead to autoimmunity [77]. Several molecules of viral or bacterial origin
were found in RA synovium [78, 79, 80]. These particles are thought to be cross-
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reactive with endogenous molecules and lead to the deregulation of the immune
response. It has been shown that the gp110 protein of Epstein-Barr virus contains
the amino-acid sequence QKRAA that is also found in the HLA-DR1 molecule
of the host genetically predisposed for RA [81]. Similarly, cross-reactive antibod-
ies against proteus mirabilis proteins, hemolysin and urease, recognise HLA-DR
antigen and type XI collagen respectively, and occur in RA sera correlating with
the biochemical markers of disease activity [82, 83]. Besides traces of protein, also
EBV nucleic acids occur in the synovial fluid of RA patients [84]. The reactivity
for self-antigens is also believed to be due to the escape of the auto-reactive cells
from the negative selection. Recently, it was reported that the self reactivity of T
cells is possibly caused by the low signaling ability of the T cell receptor pathway
[85]. In those cells, the response to self-antigen is below the threshold, and as a
result they are recognized as tolerant. Autoimmune T cell clones in synovial fluid
have been shown to lack the expression or phosphorylation of TCR-ζ, probably
due to the interaction with the synovial milieu, and thus have an acquired TCR
signaling deficiency [85]. Therefore, upon recognition of the auto-antigen, T cells
in RA neither proliferate nor express IL-2 but are rather in quiescent state. Nev-
ertheless, TCR signaling deficient T cells express INF-γ and IL-17 what results in
the activation of synovial macrophages, fibroblasts and dendritic cells. Further-
more, they are potent stimulators of antibody production by B cells. Similarly,
autoimmune B cells escape counter-selection at tolerance checkpoints both in the
bone marrow and in the periphery [86]. Elevation of B lymphocyte stimulator
(BLyS), an essential survival factor of B cells belonging to TNF-α cytokine family,
in the fluids of RA patients could be responsible for the occurrence of self-reactive
B cells [87].
Production of autoantibodies Self reactive T cells release proinflammatory cy-
tokines and promote the production of immunoglobulins directed to self antigens
by B cells. Both cytokines and autoantibodies could be detected at increased levels
even years before the first symptoms of RA [11, 12, 13, 14]. Although auto-reactive
T cells transferred to arthritis-susceptible rat strain could actually transfer the
RA-like disease [88], which provided one of the main arguments underscoring the
crucial role of T cells in the pathogenesis of inflammatory arthritis, other studies
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suggest that autoimmune B cells producing autoantibodies play a predominant role
in the pathogenesis of RA [89]. There is evidence for deposition of antibodies and
complements in the RA synovium [90]. The first described human autoantibodies
are rheumatoid factors (RF) being also the most frequently detected autoantibod-
ies in RA patients. RF reacts with the Fc part of immunoglobulins class G, M and
A (IgG, IgM and IgA) and IgG RF is considered to be related with more severe
inflammation then IgM RF. It has been suggested that the binding of RF to an
antibody-antigen complex might be followed by fixation of complement and sub-
sequent attraction of inflammatory cells and their accumulation in the synovium,
where they engulf immune complexes and release proteolytic enzymes. Therefore,
the involvement of RF may result in inflammatory arthritis. Even though RF
are not fully specific for RA, since it is present in 10% of healthy population,
several other chronic inflammatory diseases and patients with chronic infection,
it has been accepted as one of the American College of Rheumatology (ACR)
criteria for RA [91, 92, 93, 94, 95]. In contrast, a remarkable specificity of 98%
for RA characterises the antibodies directed to citrullinated peptides (anti-CCP)
[96, 97, 98]. Anti-CCP autoantibodies recognize diverse peptides that undergo
posttranslational modification of arginine deimination also called citrullination
performed by peptidylarginine deiminases (PADI). Among the antigens recognized
by anti-CCP antibodies are citrullinated fibrin and citrullinated vimentin [98, 99].
Even though anti-CCPs are present very early in the disease, predict radiographic
progression and are associated with HLA-DRB1; they are not yet included in the
ACR criteria [100, 101, 102]. Nevertheless, at present, RF concomitantly with anti-
CCP show the best predictive value, especially in smokers, over genetic markers
for development of RA [103, 104]. Autoantibodies reactive with type II collagen
(CII), vimentin, decorin, enolase and aldolase A have also been described in RA
[98, 105, 106, 107]. Moreover, several of identified auto-antigens have high ho-
mology to antigens from pathogenic organisms, and thus support the hypothesis,
that some auto-specificities of immune cells arise from cross-reactivity of the ho-
mologous epitope. Most interestingly, autoimmune-prone mice that were lacking
the TLR adaptor protein MyD88, had markedly reduced autoantibody titers di-
rected for chromatin, Sm, and rheumatoid factor [108]. Therefore, it is suggested
that the innate immunity activation has a promoting effect on the production of
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autoantibodies by B cells. Reversely, autoantibodies, which recruit complement
proteins, can induce innate immunity since complement factors such as C1q are
potent inducers of innate immunity response. Furthermore, it has been suggested
that both autoantibodies and the initiation of the inflammatory cascade via the
alternative complement pathway, which is unrestrained in RA joint, as the car-
tilage lacks the usual regulatory proteins of the complement system, are needed
for the maintenance of the inflammation in RA [90]. Taking into account the fre-
quent presence of the autoantibodies even before the onset of RA symptoms, in
the first part of the thesis I focused on the identification and characterisation of
novel autoantibodies and their possible functional role in RA.
1.3.2 Destruction of cartilage and bone in RA
Matrix metalloproteinases in RA
The extracellular matrix in a healthy articular cartilage, formed by a highly or-
ganised network of different molecules, constitutes a healthy articular cartilage.
The proteoglycans, of which aggrecan is predominant, form a polymeric structure
forming the protein backbone. They are covalently linked to copolymer chains of
negatively charged glycosaminoglycans and non-covalently to hyaluronan. These
negatively charged aggregates attract water, swell and therefore provide protection
from friction and resiliency. On the other hand, the structural rigidity of the car-
tilage is conferred by fibers of collagen. Type II collagen is predominant, however
types IX and XI also contribute to the formation of fibrils. When type II collagen is
destroyed it becomes replaced with type I collagen, which differs in the functional
properties. The loss of type II collagen and aggrecan essentially contributes to
the progression of joint destruction in RA. Activated RASF from the hyperplastic
synovium invade aggressively into the cartilage via breakdown of collagen type II
and aggrecans [109, 110, 111]. Isolated RASF sustain their activated phenotype
for generations even without any signals from the immune cells. The most striking
evidence for the intrinsic activation of RASF comes from the SCID mouse studies
[17, 112]. In the SCID mouse model of RA, normal human cartilage and RASF are
co-implanted on the sponge under the renal capsule of immunodeficient mice (Fig-
ure 4). It has been shown that 60 days after co-implantation, RASF aggressively
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invaded into the cartilage [17].
Human 
cartilage 
RASF 
Human 
cartilage 
Figure 1.4: SCID mouse model of RA. Normal human cartilage and RASF are
coimplanted to immunodeficient SCID mouse into the fat tissue under
the renal capsule. 60 days after implantation mouse is sacrificed and
the human cartilage with invading RASF analysed.
The molecular basis of RASF activation is characterized by an abnormal expression
of protooncogenes and an induction of matrix-degrading enzymes such as MMPs
and cathepsins [113, 114]. Therefore, RASF are referred to as cells with an acti-
vated phenotype. MMPs are involved in the tissue degradation, since they have
proteolytic activity towards components of the extracellular matrix. Moreover,
they were described to play a role in the cleavage of cell surface receptors, the re-
lease of FasL and activation or deactivation of chemokines [115, 116]. MMPs have
been divided into 5 groups according to their substrate specificities. Collagenases
(MMP-1, -8, -13) target collagens, the galetinases (MMP-2 and -9) degrade type
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IV collagen in the basement membrane, stromelysins (MMP-3, -10 and -11) have
non-collagen matrix proteins for substrates. Two other groups are membrane-type
MMPs (MMP-14, -15, -16, -17, -24, -25) and a diverse subgroup of MMP-7, -11, -
12, -20 and -23. Two collagenases, MMP-1 and -13 are rate limiting in the collagen
degradation process and thus are believed to have a key role in the pathogenesis of
RA [117, 118]. Moreover, MMP-13 has also activity towards aggrecan. The ma-
jority of MMP-1 is of synovial cell origin, while MMP-13 is produced mainly by
chondrocytes in the arthritic cartilage. Moreover, MMP-2, -3 and -9, that have pro-
teolitic specificities also against non-collagen matrix components are also found at
increased levels in RA joints [117, 118]. The release of fragments of cleaved matrix
components into the circulation is believed to stimulate an autoimmune response
in the susceptible individuals [119]. Even though the expression of MMPs is in-
duced by TNF-α and IL-1β, the invasive RASF have been shown to have increased
basic levels of MMPs as shown in the SCID mouse model and in vitro cultures of
RASF. MMPs have natural inhibitors, tissue inhibitor of matrix metalloproteinase
(TIMP) that are elevated in RA joint. The levels of TIMPs are however lower than
those of MMPs and therefore, TIMPs are not sufficiently effective [120]. In the
SCID mouse model of RA the overexpression of TIMP-1 and TIMP-3 in RASF
resulted in a reduction of their invasiveness [121]. Paradoxically, overexpression of
TIMPs seemed to increase cell growth and invasion in collagen induced arthritis
model [122]. There have been attempts to design effective synthetic inhibitors of
MMPs that could be used as a treatment for RA, unfortunately none has proved
successful. Therefore, studying the cellular and molecular mechanisms that lead to
the increased production of MMPs in RA might provide targets for therapy. The
promoters of MMP-1, -3, -9 and -13 contain binding sites for AP-1, which is located
in the proximity of transcription starting point and is essential for the gene expres-
sion [123]. AP1 can interact with other transcription factors, like Ets that binds
to polyoma virus enhancer activator-3 (PEA-3/ETS) sites. Furthermore, MMP-1
promoter contains another AP-1 binding site at -1602 base pairs upstream from
the transcription starting point. IL-1 and TNF-α stimulate expression of MMPs
via MAPK pathway leading to binding of AP-1 and Ets to their binding sites in the
promoters of MMPs and via targeting of another transcriptional activator, nuclear
factor ’kappa-light-chain-enhancer’ of activated B-cells (NFκB) to the promoters
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of MMP-1, -3 and -9. Even though the promoter of MMP-13 does not contain
the binding site for NFκB, inhibiting NFκB decreases the induction of MMP-13
expression in stimulated cells. Transforming growth factor β (TGF-β) is another
regulator of expression of MMPs which can have both stimulatory and repressive
effects [124]. Moreover, it has been described that the expression of MMP-1 and
MMP-13 is regulated by epigenetic modulations [124, 125]. Since there is accu-
mulating evidence for the aberrations in the epigenetic code in RA, in the second
part of my thesis I focused on the characterisation of histone acetylation in the
promoter of MMP-1.
Serine proteases in RA
Several members of another class of proteases, serine proteases, were reported to
contribute to the pathogenesis of RA [126, 127, 128, 129, 130]. Serine proteases
such as urokinase-type plasminogen activator (uPA), plasmin, tissue plasminogen
activator (tPA), thrombin and trypsin have increased activity in RA. Increased
expression and activity of uPA, which is an enzyme responsible for processing
plasminogen into plasmin, was observed in the lining layer of RA synovial tissues
when compared to synovial tissues from OA patients or healthy individuals [130].
Also the expression of two other molecules involved in the uPA signalling belong-
ing to the cell-associated fibrinolytic system, the specific uPA receptor (uPAR)
and the plasminogen activator inhibitor-type 1 (PAI-1), were reported to be in-
creased in the synovial tissues of RA joints and in RASF [130, 131]. Interestingly,
upregulated fibrinolitic system was found to contribute to the spontaneous and
uPA-challenged invasion and proliferation of RASF [131]. In addition, deficiency
of the zymogen of plasmin, plasminogen, was described to be protective in the col-
lagen induced arthritis (CIA) mouse model of RA [132]. Similarly, mice deficient
in uPA had decreased incidence and severity of CIA. Even though the develop-
ment of the autoantibodies was not different compared to the wild type mice, the
infiltration of inflammatory cells into synovial tissues as well as inflammation reac-
tion were impaired in the plasminogen activator system deficient mice. Therefore,
plasmin is thought to be a key player in the early phase of pathologic changes of
CIA in mice and possibly of RA in human. Thrombin-like activity was reported
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to be significantly higher in RA than in OA synovial fluids and correlated with
cathepsin B activity [129]. Furthermore, thrombin enhanced the proliferation of
synovial fluid cells as well as the release of IL-8 by them. Thus, thrombin was
concluded to be involved in promoting inflammation through the production of
IL-8 and the recruitment of leukocytes, which release cathepsin B into the syn-
ovial fluid. Another serine protease, trypsin-2 of human origin was shown to be
capable of cleaving collagen type II and was detected in the RA synovial tissue
as well as in the synovial fluid of affected joints [127]. Therefore, it was proposed
to be a possible contributor to the pathogenesis of RA via degradation of colla-
gen type II. Serine proteases cleave their substrates in a two-step process. First
the catalytic serine by a nucleophilic attack on the peptide bond of the substrate
causes release of a new N-terminus and forms a covalent bond with the substrate.
Next, the bond between the protease and the substrate is hydrolysed and the
protease released [133]. Serine proteases have their natural inhibitors which con-
stitute a protein family of serpins (serine protease inhibitors). Serpins are the
largest and most diverse family of protease inhibitors [134] containing members in
higher animals, nematodes, insects, plants, bacteria, archea and viruses [135, 136].
The members of the serpin family are classified into 16 groups according to the
filogenetic analysis. The majority of serpin family members have inhibitory ac-
tivity towards serine proteases and they share the mechanism of inhibition. They
typically have three β-sheets and eight or nine α-helices. They also contain an
exposed reactive centre loop (RCL) in the C- terminal part [137]. RCL determines
target specificity and is responsible for the interaction with serine proteases form-
ing a bait. If RCL is not cleaved, serpin is in a stressed conformation. When the
serine protease cleaves RCL it forms a covalent bond with the serpin and causes
its transition to the relaxed conformation [138, 139]. During the transition RCL
fits to one of the β-sheets of serpin carrying conjugated protease to the opposite
site of the serpin molecule also causing a change in its conformation. In this new
conformation the serine protease hydrolyses the covalent bond with the serpin
extremely slowly [140]. In the meanwhile the complex serine protease-serpin is in-
ternalised to the cell where it undergoes proteotolytic degradation. The majority
of serpins function extracellularly, they play a role in regulation of the proteolytic
cascades in blood clotting (e.g. antithrombin), the inflammatory response (e.g.
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antitrypsin, antichymotrypsin) and tissue remodelling (e.g. PAI-1). Deficiency of
serpins in humans results in diverse pathological states such as emphysema, cirrho-
sis, thrombosis, dementia, cardiovascular disease and tumor progression [141, 142].
Since one of the serpins serpin E2 was identified in this work as an autoantigen
in RA, I further characterised the distribution of specific anti-serpin E2 antibod-
ies and whether the binding of specific autoantibodies influences the inhibitory
activity of serpin E2.
Osteoclastogenesis
Destruction of the cartilage in RA is accompanied by the activation of pathways
that result in bone degradation. Osteoclasts are the cells responsible for dissolving
bone structures. An increased formation of osteoclasts in the synovium is one of
characteristic features in the pathogenesis of RA. Monocyte precursor cells express
on their surface the receptor activator of NF-κB (RANK) belonging to the TNF
receptor family. Stimulation of these cells by the RANK ligand (RANKL) leads to
their maturation into osteoclasts in a process of osteoclastogenesis. RANKL was
found to be present at sites of bone erosion in RA and is known to be produced by
RASF [143]. TNF-α and IL-1β induce osteoclastogenesis via upregulation of bone
morphogenetic protein-2 and -6 in RASF [144]. Since RASF have the potential to
drive cartilage and bone degradation by producing MMPs and stimulating osteo-
clastogenesis, it is therefore suggested that they could be driving the destruction
of the joints in RA.
1.3.3 Hyperplasia of synovium
In a normal joint, the lining layer of the synovium composed of synovial fibroblasts
and macrophages is only around two cells thick. In RA, however, synovial lining
consists of up to 8 cells in depth (Figure 5). Also the sublining layer of the
synovial tissue which is built by the connective tissue is characterised by increased
cellularity. In RA, the normally flat surface of the synovium is highly folded and
therefore the synovial surface is increased by even two orders of magnitude. It
has been reported that synovial hyperplasia correlates with joint erosions in RA
[145, 146]. Surprisingly, the levels of cell division in hyperplastic synovium do not
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appear to be significantly increased [20]. Hyperplasia can be partly attributed to
the active retention and promotion of survival of infiltrating immune cells by the
resident stromal cells as discussed beforehand. Nevertheless, the increased numbers
of resident RASF and macrophages also contribute significantly to the formation
of the hyperplastic synovium. It remains a question of debate whether RASF have
increased levels of proliferation. Qu et al. determined the that the expression
of markers of proliferation such as proliferating cell nuclear antigen (PCNA), c-
myc, and the nucleolar organizer regions (NOR) are increased in RASF of the
synovial lining layer [147], however this result was not confirmed by other studies
where the expression of Ki-67, the mitosis rate, and the 3H-thymidine uptake, as
well as PCNA and NOR showed no difference between RASF and control cells
[148, 149, 150]. In contrast, it is generally accepted that RASF are resistant to
apoptosis and this accounts at least partially for their increased accumulation in
the synovium.
Resistance to apoptosis
Increased resistance to induced apoptosis is one of the most characteristic features
of RASF. RASF were shown to be resistant to apoptosis induced by TRAIL, FasL
and TNF-α [37, 151, 152]. The respective receptors, TRAIL receptor, Fas and
TNF receptor I (TNFRI) contain the death domain, which, upon binding of a
corresponding ligand to the receptor, is bound by Fas-associated protein with the
Death Domain (FADD). FADD is an adaptor molecule, which recruits caspase-8
to the receptor resulting in the formation of the death inducing signaling complex
(DISC), activation of cysteine protease cascade and ultimately in apoptosis. De-
spite expressing all three types of receptors, RASF are resistant to Fas, TRAIL and
TNF-α mediated cell death. Furthermore, the resistance of RASF to apoptosis can
not be explained by the absence of apoptosis inducing ligands since soluble TRAIL,
FasL and TNF-α were found at increased levels in synovial fluids of patients with
RA compared with OA. Interestingly, it has been shown that RASF produce in-
creased levels of the anti-apoptotic molecule small ubiquitin-like modifier (SUMO)
-1/sentrin which is known to bind to the cytoplasmic domains of Fas and TNFRI
and thereby to protect cells from both FasL and TNF-induced cell death. Franz et
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Figure 1.5: Hyperplastic synovium in RA has increased thickness of intimal lining
layer. In OA the lining layer is two cells thick (A) and in RA it has
6-8 cells in depth (B).
al. has shown that SUMO-1 was overexpressed in RASF aggressively invading into
cartilage in patients as well as in the SCID mouse model [153]. However, SUMO-1
could not be shown to be localised in the cytoplasm in RASF, but was rather
present in the nucleus, mainly in the subnuclear structures called promyelocytic
leukemia (PML) nuclear bodies [154]. Therefore, SUMO-1 failed to interact with
the death domains of Fas and TNFRI in RASF. Nevertheless, in the absence of
SUMO-1, RASF were prone to FasL induced apoptosis. Further investigations of
the role of SUMO-1 in RASF have demonstrated that the intrinsic overexpression
of SUMO-1 in RASF leads to the accumulation of the pro-apoptotic DAXX in the
PML nuclear bodies. DAXX is therefore retained in the PML and can not exhibit
its pro-apoptotic functions, which contributes to the resistance of RASF to Fas
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induced apoptosis [154]. Moreover, SUMO specific protease SENP1 was shown to
be downregulated in RASF and its re-expression leads to an increased apoptotic
response induced by FasL.
SUMO
SUMO-1 together with SUMO-2, -3 and -4 belong to the ubiquitin-like protein
family [155] and they modulate proteins by conjugating to them in a reaction
of sumoylation. Sumoylation, analogously to ubiquitination, is a reversible post-
translational modification. It is a multi-step reaction initiated by a cleavage of a
precursor form of SUMO to a mature protein by a sentrin specific protease (SENP)
[156, 157]. Three enzymes take part in the covalent attachment of SUMO to the
substrates; E1 activating enzyme, E2 conjugating enzyme and E3 - a SUMO ligase
[158, 159]. Reversely, SENPs deconjugate SUMO from substrates by cleaving the
isopeptide bond [156, 157]. Up to date there are six SENP homologues identi-
fied in humans (SENP1, 2, 3, 5, 6 and 7) [160]. They differ in the localization
and specificity towards different isotypes of SUMO. SENP1 is a nuclear protein
mainly localized in the PML nuclear bodies. It has the highest specificity towards
SUMO-1, but also can cleave SUMO-2 and -3 [161, 162]. SUMO-1, when bound
to substrates, can influence their properties such as stability, localization, inter-
action with other proteins and activity [156, 163, 164]. A range of transcription
factors including c-Jun, Ets1 and C/EBP have been reported to be substrates for
sumoylation. The majority of transcriptional activators, when SUMOylated, show
decreased activity in inducing transcription, however some transcription activators
such as Ikaros, APA-1, CREB, ER, FAT1, HIF1a, HSF, MITF, P45/NF-E2, p53,
and Tcf-4 have, on the contrary, higher activity in the SUMOylated form [165].
Similarly, a range of transcription inhibitors are known to be SUMO modified.
PML, DAXX, histone deacetylase 1 and 4 (HDAC1 and 4) are known to be post-
translationally modified by SUMO-1 and this modification is suggested to increase
their activity as negative regulators of transcription [166, 167, 168, 169]. However,
the reports on the influence of sumoylation on the activity of HDAC4 are not con-
clusive. While a sumoylation-deficient mutant of HDAC4 has a slightly decreased
ability to repress the transcription, the nuclear transport of HDAC4 depends on
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the modification by SUMO-1. This implies that sumoylation of HDAC4 rather
contributes to the change in the localisation of HDAC4 than influence the activity
directly. HDAC4 was reported to co-localise with PML in the nuclear bodies in
neurons in neuronal intranuclear inclusion disease [170, 171]. Gao et al observed
that HDAC4, 5 and 7 are localised to PML nuclear bodies and the localisation
of HDAC7 into PML promoted the transcription of MMP-10 [172, 173]. Since it
is known that the levels of SUMO-1 are increased while SENP1 is decreased in
RASF I studied whether the re-expression of SENP1 could regulate the localisa-
tion of HDAC4 to the specific promoter sites leading to the regulation of gene
expression. I focused on the regulation of MMP-1 since it is overexpressed by
RASF and is rate limiting for the cartilage destruction in RA.
1.4 Objective
1.4.1 Rationale
Different cell types such as T cells, B cells, macrophages and synovial fibroblasts
are involved in the pathogenesis of RA. Therefore, the intertwining adaptive and
innate immune responses have been proposed to have a crucial role in the disease.
Since RA is an autoimmune disorder, B cells producing autoantibodies have been
long known to be involved into perpetuation of RA. Nevertheless only since few
years it is known that autoantibodies can appear in the sera of healthy individuals,
who, few years later, develop RA. Therefore, the identification of autoantibodies
and studying their role in RA is an exciting and challenging task. It could lead
to a better understanding of the disease processes and perhaps will help in the
identification of the trigger of RA. While B cells and the adaptive immune system
have long been recognised to be essential players in the development of RA, only
recently it has been agreed that RASF have a main role in the perpetuation of RA
in the absence of the adaptive immune system. There is evidence that RASF play
a role in the innate immunity since they express a range of TLR. Moreover, since
RASF are intrinsically activated, they aggressively invade cartilage as well as have
increased survival levels. The intrinsic overexpression of an anti-apoptotic molecule
SUMO-1 in RASF renders resistance to apoptosis after stimulation with apoptosis
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inducer FasL. It has been shown that the resistance to apoptosis can be broken in
RASF by decreasing levels of sumoylation. Even though SUMO-1 is a modulator
of many proteins including transcription factors and epigenetic modulators, it
has never been investigated whether the characteristic overexpression of SUMO-
1 in RASF could promote changes in gene expression pattern and result in the
aggressive phenotype of cells. We hypothesized that the increased levels of SUMO-
1 modified proteins in RASF could lead to an increase in the production of MMPs
and therefore promote the aggressive behaviour of cells.
1.4.2 Aims
A subset of B cells in RA shows autoimmune reactivity and, as a result, produces
autoantibodies. The autoantibodies have been suggested to play a role in triggering
and maintenance of RA, however, neither of these phenomena has been assigned
to a particular known autoantibody species. Therefore in Chapter 2 I report
the work focusing on the identification of novel autoantibodies in RA. Since we
identified autoantibodies directed against serpin E2, a known inhibitor of serine
proteases, we investigated the influence of the interaction of serpin E2 with serpin
E2 directed autoantibodies on the function of serpin E2. Synovial fibroblasts play
a key role in the joint destruction in RA and produce large amounts of matrix
degrading enzymes and cytokines. The intrinsic activation of RASF might be a
result of overexpression of SUMO-1 as well as epigenetic changes influencing gene
expression pattern of MMPs and cytokines. Previous studies in our group have
shown that the intrinsic overexpression of SUMO-1 in RASF leads to the resistance
of the cells to induced cell death. Even though it is known that sumoylation
can influence gene expression and the overexpression of SUMO-1 paralleled by a
decrease in SENP1 levels is characteristic for RASF, it has never been studied
whether this could contribute to the aggressive phenotype of RASF by influencing
the expression of MMPs. In Chapter 3 I assessed the levels of expression of MMP-
1 in RASF transfected with SUMO specific protease SENP1 in comparison to
mock transfected cells. Since the levels of MMPs were downregulated in the cells
overexpressing SENP1 we further studied the mechanism of this downregulation.
In summary, showing the functional role of aberrations in the sumoylation pathway
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as well as epigenetic changes that could be partially due to the modified levels of
SUMO-1 and SENP1 in RASF, additional substantial prove is provided to the
body of evidence for the intrinsic activation of RASF.
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Objective. To search for novel autoantibodies in
patients with rheumatoid arthritis (RA) in an effort to
better understand the processes of joint destruction in
this disease.
Methods. Using a modified SEREX technique and
complementary DNA derived from RA synovium, serpin
E2 was identified as a novel autoantigen and was
analyzed by immunohistochemistry. Levels of anti–
serpin E2 autoantibodies in serum and synovial fluid
from patients with RA, osteoarthritis (OA), psoriatic
arthritis, and ankylosing spondylitis, and/or from
healthy individuals were assessed by enzyme-linked
immunosorbent assay. Since serpin E2 is an inhibitor of
serine proteases, we studied the inhibitory activity of
serpin E2 toward its target, urokinase plasminogen
activator (uPA), in vitro in the presence of isolated
anti–serpin E2 autoantibodies and in vivo using the uPA
activity assay.
Results. We identified autoantibodies against ser-
pin E2 by the SEREX technique. Serpin E2 was overex-
pressed in RA synovial tissues as compared with OA
synovial tissues. Significantly higher levels of anti–
serpin E2 autoantibodies were present in samples of
synovial fluid (28%) and serum (22%) from RA patients
as compared with OA patients (0 and 6%, respectively)
or with healthy individuals (6% of sera). Most impor-
tantly, anti–serpin E2 autoantibodies isolated from RA
sera reversed the inhibitory activity of serpin E2 by 70%.
Furthermore, the levels of anti–serpin E2 autoantibod-
ies correlated with the uPA activity in vivo.
Conclusion. This study characterizes a functional
property of a novel autoantibody in RA. Since anti–
serpin E2 autoantibodies interfere with the inhibitory
activity of serpin E2 toward serine proteases, they might
facilitate the joint destruction in RA.
Rheumatoid arthritis (RA) is a chronic auto-
immune disease characterized by joint destruction.
While it is known that persistent activation of the
immune system in RA leads to autoimmunity, the trigger
that activates the immune response remains unclear.
Nevertheless, increased levels of cytokines and autoan-
tibodies may be detectable years before the first symp-
toms of RA (1–4). In 1992, Silman et al (1) reported the
identification of autoantibodies in serum samples from
healthy subjects as many as 10 years before they devel-
oped RA.
The autoantibodies most frequently detected in
RA patients are rheumatoid factor (RF) and antibodies
directed toward citrullinated peptides (anti-CCP). Even
though RF is not specific for RA, since it is present in
10% of the healthy population, in patients with several
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other chronic inflammatory diseases, and in those with
chronic infection, it has been accepted as one of the
American College of Rheumatology (ACR) criteria for
RA (5–8). In contrast, anti-CCP antibodies have a
remarkable 98% specificity for RA (9–11). Even though
anti-CCP antibodies are present very early in the dis-
ease, predict radiographic progression, and are associ-
ated with HLA–DRB1, they are not yet included in the
ACR criteria for RA (12–14). Citrullinated fibrin and
citrullinated vimentin are among the antigens recog-
nized by anti-CCP antibodies (11,15). Several other
autoantibodies have been described thus far in RA,
including autoantibodies reactive with type II collagen,
decorin, enolase, and aldolase A (16–19).
Antibody-producing plasma cells and B cells are
key players in the inflammatory process of the disease,
and depletion of B cells using anti-CD20 antibodies has
been approved for the treatment of RA (20). Nonethe-
less, it is still not clear how they contribute to the
pathogenesis of RA. The identification of autoantibod-
ies and the definition of their possible pathologic role
are therefore a challenging task.
Serologic analysis of a recombinant human com-
plementary DNA (cDNA) expression library (SEREX)
is a valuable screening method used extensively for the
identification of autoantibodies related to different dis-
eases (21–26). The SEREX technique allows for the fast
identification of all cDNA-encoded proteins in a given
tissue sample that are recognized by autologous sera.
The main advantage of SEREX over classic methods
such as Western blotting is the possibility of identifying
a broad spectrum of autoantibodies that are reactive
with proteins expressed extracellularly and intracell-
ularly, since it involves the screening of a complete gene
expression library.
In the present study, we used a modified SEREX
technique and a cDNA library obtained from RA syno-
vial tissue as a screening method to identify novel targets
for autoantibodies in RA. We found increased levels of
autoantibodies to serpin E2 in synovial fluid and serum
from patients with RA. In search of a functional role of
these autoantibodies, we found that anti–serpin E2
autoantibodies interfered with the inhibitory activity of
serpin E2 and, thus, might contribute to the destructive
process in the joints of RA patients.
PATIENTS AND METHODS
Synovial fluid and serum samples. Synovial fluid sam-
ples were obtained from 44 patients with RA, 18 with osteo-
arthritis (OA), 10 with psoriatic arthritis (PsA), and 10 with
ankylosing spondylitis (AS) and were stored at –80°C. Before
analysis, synovial fluid samples were treated with hyaluroni-
dase (1 mg/ml for 1 hour at room temperature). Serum
samples were obtained from 183 RA patients (134 women and
49 men with a mean age of 46 years [range 13–75 years]; RF
negative in 37), 64 healthy subjects matched for sex and age
with the RA patients (41 women and 23 men with a mean age
of 45 years [range 24–75 years]), 34 OA patients (20 women
and 14 men with a mean age of 65.5 years [range 40–83 years]),
11 PsA patients (4 women and 7 men with a mean age of 44
years [range 25–52 years]), and 14 AS patients (5 women and
9 men with a mean age of 41 years [range 26–52 years]). Serum
samples were stored at –80°C until analyzed.
The synovial fluid and serum samples were obtained
from clinics in Zurich, Switzerland, Manchester, UK, and
Erlangen, Germany. All RA patients fulfilled the ACR (for-
merly, the American Rheumatism Association) criteria (27).
All experiments were performed after obtaining informed
consent from the study participants.
Detection of autoantibodies in RA synovial fluid by
SEREX. We used a modified SEREX technique in which
synovial fluid was included for the identification of novel
autoantibodies in RA patients. A human RA synoviocyte 
cDNA library kit obtained from Stratagene (Cedar Creek, TX)
was used for these analyses according to the manufacturer’s
instructions and as previously described (21–25). XL1-Blue
MRF cells were transfected with a premade  phage RA
synovium cDNA library, and the expression of recombinant
proteins was induced with IPTG. Recombinant proteins were
transferred onto nitrocellulose membranes (Schleicher &
Schuell, Dassel, Germany). Synovial fluid from a patient with
RA was preabsorbed against bacterial and  phage proteins
prior to analysis. Membranes were blocked with 5% milk in
Tris buffered saline (TBS; 20 mM Tris HCl, 150 mM NaCl) and
incubated overnight at 4°C with synovial fluid diluted 1:200.
Reactive antibodies were detected with goat anti-human IgG
alkaline phosphatase–conjugated antibodies (Sigma-Aldrich,
Basel, Switzerland) and visualized with nitroblue tetrazolium/
BCIP (Roche, Reinach, Switzerland). The positive clones were
confirmed by a second round of screening, and plaques were
isolated. For excision of the plasmids, the SOLR bacterial
strain was infected with the isolated phagemid. In vitro excision
of the plasmid DNA was performed using the ExAssist helper
phage provided in the cDNA library kit. DNA was isolated and
sequenced using T7 primers (Microsynth, Balgach, Switzer-
land).
Identification of the sequences of the detected autoan-
tigens was performed using the National Center for Biotech-
nology Information gene bank (online at http://
www.ncbi.nlm.nih.gov) by sequence alignment in BLAST.
Immunohistochemistry for serpin E2 in RA and OA
synovial tissues. Synovial tissues were obtained from RA (n 
10) and OA (n  10) patients undergoing joint replacement
surgery. Tissue samples were immediately fixed in paraformal-
dehyde and embedded in paraffin. Subsequently, 3-m sec-
tions were prepared. Following deparaffinization, nonspecific
binding was blocked by incubation for 1 hour in a blocking
solution (4% nonfat dry milk and 2% goat serum in TBS, pH
7.4). Slides were then incubated for 1 hour with mouse
anti-human serpin E2 IgG antibodies (a generous gift of
Marie-Christine Bouton, University Paris 7, Paris, France) at a
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concentration of 14 g/ml, followed by incubation with alka-
line phosphatase–conjugated goat anti-mouse anti-
immunoglobulins in phosphate buffered saline (Dako, Baar,
Switzerland). The antigen–antibody reaction was visualized
using Fast Red substrate (Dako). In control experiments,
primary antibodies were replaced by a mouse IgG isotype at
the same concentration. The slides were counterstained with
hematoxylin for 1 minute, dehydrated, and mounted. All steps
were performed at room temperature. A grading system of 0–3
was used to score the expression levels of serpin E2 in synovial
tissues, where 0  no expression, 1  weak expression, 2 
medium strong expression, and 3  strong expression.
Enzyme-linked immunosorbent assay (ELISA) for
anti–serpin E2 autoantibodies in synovial fluids and sera. To
establish an ELISA, conditions were optimized by using vari-
ous concentrations (10–100 ng/ml) of recombinant human
serpin E2 (R&D Systems, Abingdon, UK), a range of dilutions
(1:10–1:1000) of hyaluronidase-treated synovial fluid or sera,
and different concentrations (90–900 ng/ml) of horseradish
peroxidase (HRP)–conjugated goat anti-human IgG antibod-
ies (Jackson ImmunoResearch, Magden, Switzerland). The
following conditions were used for the analysis: plates were
coated with 100 ng/ml of recombinant human serpin E2 in a
coating buffer (0.53% Na2CO3, 0.42% NaHCO3, 0.1% sodium
azide, pH 9.6) and incubated overnight at 4°C. Nonspecific
immune interactions were blocked with 3% bovine serum
albumin (BSA) in TBS containing 0.05% Tween 20 (TBST).
This was followed by incubation with diluted synovial fluid
samples (1:200 in TBST containing 1% BSA) or sera (1:500 in
TBST containing 1% BSA) in duplicate for 2 hours at room
temperature. HRP-conjugated goat anti-human IgG antibod-
ies were added (90 ng/ml in TBST containing 1% BSA) for 1
hour.
The reaction was visualized using 3,3,5,5-
tetramethylbenzidine (TMB) substrate (BD Biosciences,
Allschwil, Switzerland), and the reaction was stopped with
10% orthophosphoric acid (Fluka, Buchs, Switzerland). As a
positive control mouse anti-human serpin E2 IgG antibodies (a
generous gift of Marie-Christine Bouton, University Paris 7,
Paris, France) detected by HRP-conjugated rabbit anti-mouse
antibodies (Dako) and visualized using TMB were used.
Plates were read at a wavelength of 450 nm. One
selected RA serum was used for preparation of the standard
curve and for normalization of the results of all of the tests that
were performed (set at 100 arbitrary units [AU]). Cutoff values
were calculated as mean  2 SD of the value in OA patients
for synovial fluid and as the mean  2 SD of the value in
healthy individuals for serum. Values below the respective
cutoff levels were considered to be in the normal range.
Isolation of autoantibodies specific for serpin E2 from
sera. Serpin E2–specific autoantibodies were isolated from
sera as previously described (28). Briefly, 4 ml of CNBr-
activated Sepharose 4 Fast Flow (GE Healthcare, Otelfingen,
Switzerland) was washed 12 times with 4 ml of cold 1 mM HCl,
pH 3, and after each washing was incubated at 4°C for 5
minutes. Conjugation of recombinant human serpin E2 or the
irrelevant autoantigen pituitary tumor–transforming gene
1–interacting protein (PTTG-1IP) (2.5 g in 2.5 ml of 0.1M
NaHCO3, 0.5M NaCl, pH 8.3, buffer) to packed CNBr-
activated Sepharose 4 Fast Flow was performed at pH 7.5 for
2 hours at 4°C, followed by 3 hours of incubation at room
temperature. The Sepharose gel was then washed with buffer
(0.1M NaHCO3, 0.5M NaCl, pH 8.3) and blocked with a 2.5
excess of 0.1M Tris HCl, pH 8, for 2 hours at room tempera-
ture. The Sepharose gel was split into 1-ml portions and
washed alternately (6 times) with 3 ml of 0.1 acetate buffer, pH
3.4, containing 0.5M NaCl and 0.1M Tris HCl buffer, pH 8.0.
The gel portions were washed once with PBS and used
immediately for the isolation of antibodies from sera or were
stored at 4°C.
The capture of autoantibodies against serpin E2 was
performed by incubation of 1 ml of human serum from RA
patients or from healthy controls that had been diluted 1:4 in
PBS with 1 ml of packed gel conjugated to serpin E2 for 16
hours at 4°C on a rocking mixer. The gel was washed 6 times
with 2 ml of PBS. For elution of autoantibodies, the gel was
incubated with elution buffer (1 ml of 0.1M Na2CO3/NaHCO3,
pH 10.7) for 20 minutes at room temperature. Eluents were
neutralized to pH 7 with 0.4M HCl, and aliquots were collected
for determination of the antibody content by Western blotting.
Immediately after elution, the eluents were incubated over-
night at 4°C with preblocked Protein A/G Plus–Agarose Beads
(Santa Cruz Biotechnology, Heidelberg, Germany). Subse-
quently, the beads were washed 6 times with distilled water,
suspended in distilled water, and used immediately for further
procedures.
The presence of isolated antibodies was confirmed by
Western blot following every step of antibody purification. To
test the reactivity of the isolated anti–serpin E2 autoantibod-
ies, aliquots were used for precipitation of recombinant human
serpin E2. Briefly, 25 l of anti–serpin E2 or irrelevant
anti–PTTG-1IP autoantibodies conjugated to Protein A/G
Plus–Agarose Beads were incubated overnight with 100 ng of
recombinant human serpin E2. Next, the beads were washed 6
times with distilled water, and the amount of precipitated
serpin E2 was analyzed by Western blotting. Samples were
suspended in Laemmli buffer, separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, and transferred to
nitrocellulose membranes for immunodetection as previously
described (29), using HRP-conjugated goat anti-human IgG
antibodies (Jackson ImmunoResearch) or goat anti–serpin E2
(R&D Systems) followed by HRP-conjugated rabbit anti-goat
IgG (Jackson ImmunoResearch).
Functional analysis of serpin E2 activity by the uroki-
nase plasminogen activator (uPA) activity assay. The inhibi-
tory activity of recombinant human serpin E2 toward its target,
uPA, was determined using a uPA activity assay kit (Chemi-
con, Temecula, CA) according to the manufacturer’s instruc-
tions. Briefly, 100 ng of recombinant human serpin E2 was
preincubated for 1 hour with Protein A/G Plus–Agarose
Beads. The beads were left uncoupled or were coupled to
anti–serpin E2 autoantibodies that had been isolated from the
sera of healthy subjects (n  4) and RA patients (n  4) or to
irrelevant anti–PTTG-1IP autoantibodies isolated from the
sera of RA patients. To each urokinase reaction, the amount of
added antibodies against serpin E2/anti–PTTG-1IP was the
same as the amount isolated from 1 ml of sera diluted 1:4.
Next, 5 units of uPA, a uPA substrate, and assay buffer were
added. In the positive control reaction, only uPA, uPA sub-
strate, and assay buffer were used. Reactions were performed
overnight at 37°C. The activity of uPA was then measured with
an ELISA reader at 405 nm.
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Statistical analysis. Student’s t-test and the Mann-
Whitney U test were used to compare 2 groups of parametric
and nonparametric data, respectively. For assessing correla-
tions, r2 values were determined with Pearson’s correlation
coefficient. P values less than or equal to 0.05 were considered
statistically significant.
RESULTS
Identification of novel autoantibodies in RA syno-
vial fluid. By modifying the SEREX technique and using
RA synovial fluid for the identification of novel autoanti-
bodies in RA, we identified 61 immunoreactive clones in
the first screening. Positivity of 9 of the clones was con-
firmed by the second screening (Figures 1A and B). The
identified clones included previously described autoreac-
tivities against vimentin, decorin, aldolase A, and the
eukaryotic translation elongation factor 1 1 (EF-11).
Moreover, we were able to identify novel autoreactive
antibodies in RA, namely, anti–PTTG-1IP, anti–glyoxalase
I, anti–connective tissue growth factor (anti-CTGF), anti–
neuregulin 1 isoform GGF2, and anti–serpin E2.
Serpin E2 as a novel target for autoantibodies in
RA. Among other proteins, serpin E2 was recognized by
autoantibodies in RA synovial fluid in the SEREX
analysis. Serpin E2 is a natural inhibitor of serine
proteases, such as plasmin, uPA, thrombin, and trypsin,
that show increased activity in RA and are implicated in
the pathogenesis of joint destruction. Since serpin E2
has been reported to play a preventive role in cartilage
degradation (30), we focused on the role of anti–serpin
E2 autoantibodies. The cDNA clone in the plaques
reactive with anti–serpin E2 autoantibodies included the
3 portion of the serpin E2 coding sequence (1,819–
1,854 bp). This region of the serpin E2 gene is in close
proximity to the region coding for the reactive center
loop (RCL), which is essential for the interaction of
serpin E2 with serine proteases (Figure 1C).
Figure 1. Identification of novel targets for autoantibodies in rheumatoid arthritis (RA) by SEREX technique. A recombinant human cDNA
expression library from an RA patient was used for screening by SEREX. RA synovial fluid was used for the identification of novel targets for
autoantibodies. A, Multiple plaques expressing 1 positive antigen clone that was reactive with synovial fluid from an RA patient as well as 1 negative
clone on a nitrocellulose membrane after a second round of screening. Results were scored as positive only when the test clones (solid arrow) were clearly
distinguishable from the control clones (open arrow). B, Targets for autoantibodies in RA identified by SEREX. Numbers in parentheses are reference
numbers for identified targets previously described as an autoantigen in RA. VIM  vimentin; DCN  decorin; ALDOA  aldolase A; EEF1A1 
eukaryotic translation elongation factor 1 1; PTTG1IP  pituitary tumor–transforming gene 1–interacting protein; GLOI  glyoxalase I; CTGF 
connective tissue growth factor; NRG1 neuregulin 1 isoform GGF2. C, Diagram of a coding sequence (CDS) of serpin E2 (the 661–1,854-bp region of
serpin E2 cDNA; accession number BC042628). The autoantibodies from RA synovial fluid were reactive with a peptide encoded by the 1,819–1,854-bp
region of serpin E2 cDNA, which is in close proximity to the reactive center loop (RCL) coding region (1,711–1,788 bp).
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Expression of serpin E2 in synovial tissues from
patients with RA and patients with OA. To investigate
the expression levels of serpin E2 in RA and OA
synovial tissues, we performed immunohistochemical
staining using anti–serpin E2 antibodies (Figures 2A and
B). In both RA and OA synovial tissues, serpin E2 was
expressed in the cells around blood vessels (median  SD
score 2.0  0.7 in RA versus 1.5  0.7 in OA). Most
interestingly, in the synovium of patients with RA (n 10),
serpin E2 was overexpressed in both the lining layer (2.0
0.9 in RA versus 0.5  0.5 in OA; P  0.01) and the
sublining layer (2.0  0.5 in RA versus 1.0  0.9 in OA;
P  0.01) (Figure 2C). This pattern differed from that in
the synovium of patients with OA, where serpin E2 was
present mostly around blood vessels. Thus, serpin E2 was
significantly overexpressed in RA synovial tissue.
High levels of anti–serpin E2 autoantibodies in
RA synovial fluid. After serpin E2 had been identified as
a novel target for autoantibodies using the SEREX
technique, the levels of autoantibodies specific for serpin
E2 in synovial fluid samples from patients with RA (n 
44), PsA (n  10), AS (n  10), and OA (n  18) were
determined by ELISA. Anti–serpin E2 autoantibodies
were detected at significantly higher levels in RA syno-
vial fluid (mean  SD 67  66 AU) than in OA synovial
fluid (31  31 AU; P  0.05). Serpin E2–reactive
autoantibodies were increased in 28% of the RA synovial
fluid samples; in contrast, all of the OA synovial fluid
samples were in the normal range (Figure 3A). In both the
PsA and the AS patients, anti–serpin E2 autoantibodies
were present in 20% of the synovial fluid samples; how-
ever, the difference between PsA or AS samples and the
Figure 2. Expression of serpin E2 in synovial tissues from patients with rheumatoid arthritis
(RA) and osteoarthritis (OA). A and B, Immunohistochemical analysis of the expression of
serpin E2 in RA and OA synovial tissue sections. Serpin E2 was expressed throughout the
synovium in RA tissues (A) and mainly around vessels in OA tissues (B). Insets show the
respective IgG controls. (Hematoxylin counterstained; original magnification  100). C,
Scoring of immunohistochemically stained sections for the expression of serpin E2 in 10 OA
and 10 RA synovial tissue sections. The lining layer (left pair of bars), sublining layer
(middle pair of bars), and vessels (right pair of bars) were scored individually. Values are the
median and SD.   P  0.05 by Mann-Whitney U test.
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control OA synovial fluid samples did not reach statistical
significance (mean SD 43 53 AU in PsA and 58 37
AU in AS). The RA patients, therefore, had a higher
prevalence of anti–serpin E2 autoantibodies in synovial
fluid than did the OA patients.
High levels of anti–serpin E2 antibodies in RA
patient sera. Next, we analyzed whether anti–serpin E2
autoantibodies were also present in sera. Serum samples
derived from the peripheral blood of RA patients (n 
183), OA patients (n  34), PsA patients (n  11), AS
patients (n  14), and healthy individuals (n  64) were
tested for the presence of anti–serpin E2 autoantibodies.
Anti–serpin E2 autoantibodies were detected at signifi-
cantly higher levels in RA patient sera (mean  SD
125 90 AU) than in OA patient sera (86 51 AU; P
0.02) and normal sera (61  51 AU; P  0.01).
Anti–serpin E2 autoantibodies were detected in 22% of
serum samples from patients with RA. This differed
significantly from that in OA patients and healthy indi-
viduals; both groups showed 6% positive sera (Figure
3B). Furthermore, in RF-negative RA patients, 16% of
the serum samples were positive for anti–serpin E2
autoantibodies. The levels of anti–serpin E2 autoanti-
bodies in the anti-CCP–positive and anti-CCP–negative
subgroups were not statistically different. Of the PsA
sera, 9% were positive for anti–serpin E2 autoantibodies
(mean  SD 81  53 AU); this value did not differ
significantly from that in the control OA sera. In con-
trast, anti–serpin E2 autoantibodies were present in 33%
of AS sera (247  304 AU), and the values in this group
differed significantly from those in the healthy subjects
(P  0.01), the OA patients (P  0.02), and the PsA
patients (P  0.05).
Although autoantibodies against serpin E2 were
detected by the screening procedure using synovial fluid
samples, they were also similarly detected using serum
samples. Thus, RA patients showed significantly higher
levels of anti–serpin E2 autoantibodies than did OA
patients and healthy controls.
Assessment of the functional role of anti–serpin
E2 autoantibodies. Since serpin E2 has profound effects
on the remodeling of the extracellular matrix and since
the autoantibodies bind to a region of serpin E2 that lies
in proximity to the RCL, we analyzed the function of the
autoantibodies on the activity of serpin E2. To evaluate
whether the inhibitory function of serpin E2 is influ-
enced by the presence of specific anti–serpin E2 auto-
antibodies, we isolated anti–serpin E2 antibodies from
Figure 3. Levels of anti–serpin E2 autoantibodies in A, synovial fluid and B, serum from patients with osteoarthritis (OA), rheumatoid
arthritis (RA), psoriatic arthritis (PA), and ankylosing spondylitis (AS), as well as in sera from healthy controls. Levels of
autoantibodies reactive with recombinant human serpin E2 were determined by enzyme-linked immunosorbent assay. Each data point
represents a single subject; horizontal lines show the mean. Broken horizontal line represents the cutoff value for positivity; red
symbols represent subjects positive for anti–serpin E2. P values were calculated using Student’s t-test (significant at P  0.05). Tables
at the bottom summarize the data. AU  arbitrary units.
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the sera of patients with RA. As a control, we used sera
from healthy individuals. Serpin E2 was immobilized on
Sepharose beads and incubated with diluted sera from
RA patients or healthy controls. The antibodies were
eluted and then purified from the eluents by binding to
Protein A/G Plus–Agarose Beads. The isolated antibod-
ies were quantified by Western blotting.
As expected, more anti–serpin E2 autoantibodies
were isolated from the sera of RA patients (n  4;
mean  SD 42  7 densospot units) as compared with
the sera of healthy individuals (n  4; 19  3 densospot
units) (Figures 4A and B). The isolated anti–serpin E2
autoantibodies precipitated serpin E2 according to their
concentration (r2 0.76, P 0.01) (Figure 4C). We also
tested whether control irrelevant (anti–PTTG-1IP) au-
toantibodies isolated from RA sera (n  2) could
precipitate serpin E2. As expected, the irrelevant anti–
PTTG-1IP autoantibodies did not precipitate serpin E2
(Figure 4D).
Since uPA is a serine protease that is inhibited by
serpin E2, we investigated the ability of serpin E2 to
inhibit the activity of uPA in the presence of anti–serpin
E2 autoantibodies isolated from the sera of patients with
RA. We analyzed the activity of uPA in the presence of
recombinant human serpin E2 that had or had not been
preincubated with anti–serpin E2–specific autoantibod-
ies isolated from RA patients. As expected, recombinant
human serpin E2 (500 ng/ml) inhibited the activity of
uPA (Figure 5A). Most importantly, in the presence of
serpin E2–specific autoantibodies isolated from RA
patient sera, the inhibition of uPA activity by serpin E2
was diminished by a mean  SD of 69  8% (n  4).
Anti–serpin E2 antibodies isolated from normal sera
diminished the inhibition of the uPA activity by serpin
Figure 4. Precipitation of serpin E2 by anti–serpin E2 autoantibodies isolated from sera. A, Levels of autoantibodies reactive with recombinant
human serpin E2 in serum samples from healthy subjects and from patients with rheumatoid arthritis (RA) whose samples were used to isolate the
anti–serpin E2 autoantibodies. Each data point represents a single subject; horizontal lines show the mean. AU  arbitrary units. B, Detection of
autoantibodies by Western blotting with anti-human IgG antibodies (top). Shown are anti–serpin E2 autoantibodies isolated from the sera of healthy
subjects (lanes 1–4) or patients with RA (lanes 5–8) and anti–pituitary tumor–transforming gene 1–interacting protein (anti–PTTG-1IP) antibodies isolated
from an RA patient serum (lane 9). Arrows indicate IgG heavy and light chains of expected sizes. Anti–serpin E2 autoantibody levels in the respective
groups of blots were quantified by densitometry (bottom). Values are the mean and SD. C, Correlation between the amount of anti–serpin E2
autoantibodies isolated and the percentage of serpin E2 precipitated. D, Ratio of the percentage of precipitated serpin E2 per densospot unit of isolated
anti–serpin E2 autoantibodies and per densospot unit of isolated anti–PTTG-1IP autoantibodies. Values are the mean and SD.
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E2 by 49  10% (n  4). Thus, the reduction in the
inhibitory effect of recombinant human serpin E2 in the
presence of autoantibodies isolated from RA patients
was significantly higher than that in the presence of
autoantibodies isolated from healthy individuals (P 
0.05) (Figure 5A).
In the presence of irrelevant (anti–PTTG-1IP)
autoantibodies isolated from RA sera (n  2), the
inhibitory activity of serpin E2 toward uPA was not
decreased. Since isolated anti–serpin E2 autoantibodies
from different sera impaired the activity of serpin E2 to
different extents, we correlated the amount of isolated
antibodies and the respective values for the uPA activity.
Increasing quantities of antibodies, as determined by
densitometry, correlated significantly with uPA activity
(r2  0.5, P  0.05) (Figure 5B). From these experi-
ments, we conclude that anti–serpin E2 autoantibodies
impair the inhibitory function of recombinant human
serpin E2 in vitro in a dose-dependent manner.
Correlation of serum anti–serpin E2 autoanti-
body levels with uPA activity in serum and synovial fluid
in vivo. Based on the results showing in vitro the
function of isolated anti–serpin E2 autoantibodies on
the inhibitory activity of recombinant human serpin E2,
we next investigated the function of these autoantibodies
in vivo. In these analyses, we examined the uPA activity
and the anti–serpin E2 concentration in serum samples
from 38 RA patients, 5 PsA patients, and 5 AS patients
and synovial fluid samples from 10 RA patients, 5 PsA
patients, and 5 AS patients. We found that, indeed, high
levels of anti–serpin E2 autoantibodies corresponded to
high levels of uPA activity in sera (r2  0.12, P  0.02),
indicating that in vivo, serpin E2 is a less active inhibitor
in the presence of anti–serpin E2 autoantibodies (Figure
5C). In contrast, the levels of anti–serpin E2 autoanti-
bodies in synovial fluid did not correlate significantly
with the activity of uPA in synovial fluid (data not
shown). In addition, the quantities of anti–serpin E2
Figure 5. Correlation between anti–serpin E2 autoantibody levels and urokinase plasminogen activator (uPA) activity. A, Activity of uPA, as
measured in a uPA activity assay and expressed as the percentage inhibition of uPA. Down-regulation of uPA activity in the absence of recombinant
human (rh) serpin E2 (open bar), in the presence of recombinant human serpin E2 (set at 100%) (solid bar), in the presence of recombinant human
serpin E2 preincubated with anti–serpin E2 antibodies isolated from the sera of normal subjects (n  4) (open striped bar), or from the sera of
rheumatoid arthritis (RA) patients (n  4) (shaded striped bar), and in the presence of recombinant human serpin E2 preincubated with anti–pituitary
tumor–transforming gene 1–interacting protein (anti–PTTG-1IP) antibodies isolated from the sera of RA patients (n  2) (open dotted bar) are shown.
Values are the mean and SD.   P  0.05 by Mann-Whitney U test. B, Correlation between the levels of anti–serpin E2 autoantibodies isolated from
the sera of RA patients (solid squares) and normal controls (open squares) (n 4 per group) and the activity of uPA in the presence of recombinant human
serpin E2.C,Correlation between the levels of anti–serpin E2 antibodies and the activity of uPAmeasured in sera fromRA patients (n 38), PsA patients
(n  5), and AS patients (n  5). AU  arbitrary units. D, Correlation between the levels of anti–serpin E2 antibodies measured in serum samples and
the activity of uPA in synovial fluid samples from the same patients: 10 with RA, 5 with PsA, and 5 with AS.
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autoantibodies found in sera correlated significantly
with the activity of uPA in synovial fluids (r2  0.2, P 
0.05) (Figure 5D). In conclusion, the levels of anti–
serpin E2 autoantibodies in serum were associated with
the levels of activity of uPA in serum and synovial fluid.
DISCUSSION
Using the SEREX screening technique, we iden-
tified several novel targets for autoantibodies in RA.
Among the clones we identified were decorin, vimentin,
and aldolase A, for which specific autoantibodies have
already been described in patients with RA (11,17,18).
Another antigen, EF-11, has previously been shown to
be immunoreactive in Felty’s syndrome and has also
been related to RA (31). Moreover, we were able to
identify previously unknown autoreactive antibodies in
RA synovial fluid samples, namely, autoantibodies di-
rected toward PTTG-1IP, glyoxalase I, CTGF, neuregu-
lin 1 isoform GGF2, and serpin E2.
Serine proteases, such as plasmin, tissue plasmin-
ogen activator (tPA), uPA, thrombin, and trypsin, show
increased activity in RA patients and are thought to
contribute to the pathogenesis of the disease (32–36). In
a collagen-induced mouse model of RA, plasmin was
shown to be an essential component of the early phase of
pathogenesis (37). Thrombin is known to induce angio-
genesis, fibrin formation, and inflammation (38,39),
which are also the primary events in the joint destruction
in RA. RA synovial tissues were shown to exhibit
considerably increased uPA activity in the lining layer,
and RA synoviocytes were shown to be more prone to
uPA-challenged invasion and proliferation (36,40).
Specific inhibitors of serine proteases, such as
antithrombin, antiplasmin, and plasminogen activator
inhibitor 1 (PAI-1), belong to the family of serine
protease inhibitors (serpins). Serpins are classified into
16 groups according to phylogenetic analysis, with mem-
bers present in higher animals, nematodes, insects,
plants, and viruses. The majority of the serpin family
members are active serine protease inhibitors with the
reactive center loop–active site located in the C-terminal
portion. The RCL forms a bait that is targeted by a
serine protease. After the protease cleaves the RCL
domain, it is bound covalently on the catalytic serine
residue and is irreversibly inhibited. Next, the protease
bound to serpin is internalized and degraded.
Serpin E2, which is also called protease nexin
1/glial-derived nexin, is classified to clade E of the serpin
family, together with PAI-1 and myxoma virus serpin
Serp-1. Serpin E2 regulates matrix accumulation and
coagulation by inhibiting thrombin, plasmin, tPA, and
uPA. Serpin E2 was shown to be induced by proinflam-
matory cytokines in different cell types. Interleukin-1
(IL-1), transforming growth factor , and tumor necro-
sis factor  (TNF)–induced serpin E2 in neurons and
muscle cells (41,42), chronic exposure to TNF in rat
fibroblast-like synoviocytes and mouse endothelial cells
(43,44), and stimulation of human monocytes with lipo-
polysaccharide were shown to up-regulate the expres-
sion of serpin E2 (45). Recently, serpin E2 was detected
at high levels in atherosclerotic plaques and was sug-
gested to play a protective role against aggression of
proteases under inflammatory conditions (45). Most
interestingly, serpin E2 indeed prevented IL-1/basic
fibroblast growth factor–induced articular cartilage loss
through the inhibition of plasmin, thus preventing the
subsequent activation of matrix metalloproteinases
(MMPs) in rabbits (30).
Given the protective role of serpin E2 against
cartilage loss by inhibiting plasmin and by averting the
subsequent activation of MMPs (30,46), we focused on
analyzing autoantibodies against serpin E2 in RA.
We have established an ELISA with which we
measured the levels of anti–serpin E2 autoantibodies in
serum and synovial fluid from patients with RA, patients
with OA, and healthy individuals. In the present study,
we showed that patients with RA have high levels of
anti–serpin E2 autoantibodies. It might be argued that
RF present in RA patient sera could react with the
anti–serpin E2 autoantibodies and thereby amplify the
signal obtained in ELISA. We therefore analyzed RF-
negative sera from RA patients (n  37). The levels of
anti–serpin E2 autoantibodies detected in RF-negative
sera from RA patients were also significantly higher than
those in healthy controls (data not shown).
To investigate the functional significance of ele-
vated levels of anti–serpin E2 in patients with RA, we
tested the inhibitory activity of recombinant human
serpin E2 in the presence of anti–serpin E2 autoanti-
bodies isolated from human serum. We showed that the
activity of serpin E2 in vitro was decreased by anti–
serpin E2 autoantibodies isolated from sera of patients
with RA. Fewer anti–serpin E2 autoantibodies were
isolated from the sera of healthy individuals, which was
consistent with the results from the ELISA. Anti–serpin
E2 autoantibodies isolated from the sera of healthy
individuals also interfered with the activity of serpin E2,
but to a lesser extent, according to their lower concen-
tration. We conclude that the pathologically elevated
levels of anti–serpin E2 autoantibodies found in RA
ANTI–SERPIN E2 ANTIBODIES IN RA 101
CHAPTER 2. FUNCTIONAL AUTOANTIBODIES AGAINST SERPIN E2 IN
RHEUMATOID ARTHRITIS
38
patients could lead to the increased activity of serine
proteases in this disease.
Serum levels of anti–serpin E2 autoantibodies
correlated significantly with the activity of uPA in serum
and in synovial fluid. Higher levels of anti–serpin E2
autoantibodies were detected in serum than in synovial
fluid from RA patients. This could be due to infiltration
and attachment of the anti–serpin E2 autoantibodies to
serpin E2, which is overexpressed in RA synovial tissue;
this would result in a lowering of the anti–serpin E2
levels in synovial fluid. This possibility is supported by
the results showing that the serum levels of anti–serpin
E2 autoantibodies correlated significantly with uPA
activity in synovial fluid, whereas we did not observe a
correlation between uPA activity and the levels of
synovial fluid anti–serpin E2.
It remains to be elucidated whether autoantibod-
ies reduce the activity of serpin E2 through binding and
blocking of the RCL domain, which is essential for
activity, through changing the conformation of serpin E2
or through another mechanism. Analysis of the se-
quence of the cDNA coding for a fragment of serpin E2
that is reactive with the sera of RA patients by the
SEREX method showed that the autoantibodies bind to
10 amino acids in the C-terminal domain of serpin E2.
Since the RCL responsible for the inhibition of serine
proteases is located in the C-terminus, it is possible that
the autoantibodies that bind to the C-terminal portion of
serpin E2 could block the interaction of serpin E2 with
the proteases.
In RA synovial tissues, serpin E2 was expressed
in cells around blood vessels, in the lining layer, and in
the sublining layer of the synovium. In contrast, in OA
control synovial tissues, serpin E2 was mainly expressed
by cells around blood vessels. The expression of serpin
E2 in vessels has been described in normal human
arteries, but not in plasma or in circulating blood, unlike
other serpins, such as antithrombin III, antitrypsin, and
antichymotrypsin, which function as serine protease
inhibitors in the regulation of coagulation cascades (45).
Serpin E2 localized in blood vessels could be responsible
for the regulation of thrombosis or coagulation at the
tissue level or the cellular level. The increased expres-
sion and the special localization of serpin E2 in the
synovium of patients with RA could indicate that a
counterregulatory mechanism is activated to decrease
the activity of proteases and that this putative defense
mechanism is at least partly inhibited by anti–serpin E2
autoantibodies.
It is not known whether the direct blocking effect
of anti–serpin E2 autoantibodies on the function of
serpin E2 is an isolated feature of this specific antigen–
antibody complex. It is possible that other antigens are
also modified in their activities or properties when
bound to specific autoantibodies. From this viewpoint,
the production of autoantibodies could play an impor-
tant role in the pathogenesis of RA, rather than being an
epiphenomenon. Pullerits et al (47) recently reported
that the presence of autoantibodies specific for receptor
for advanced glycation end products (RAGE) coincides
with the amelioration of erosions in RA, which suggests
a protective role of anti-RAGE autoantibodies against
inflammation in the synovium. Here, in contrast, we
found that autoantibodies specific for serpin E2 might
worsen the disease, since autoantibodies isolated from
the sera of patients with RA reversed the protective
inhibitory activity of serpin E2. Anti–serpin E2 autoan-
tibodies might therefore favor the proteolytic milieu in
RA joints, as well as enhance inflammation, since it has
been reported that increased serine protease activity
intensifies inflammation (48). It would therefore be
interesting to investigate whether RA patients with
increased levels of anti–serpin E2 autoantibodies re-
spond to B cell depletion therapy with, for example,
anti-CD20 antibodies, as has been shown with some
autoantibodies in systemic lupus erythematosus patients.
It must also be considered that serpin E2 inhibits
a wide range of proteases involved in the pathogenesis of
RA. Thus, it is probable that the presence of autoanti-
bodies specific for serpin E2 could have a greater effect
on the destruction of cartilage than just increasing the
activity of uPA (Figure 6). However, it is difficult to
evaluate the extent to which anti–serpin E2 antibodies
Figure 6. Hypothetical pathways influenced by the interaction of
serpin E2 with anti–serpin E2 autoantibodies. The occurrence of
anti–serpin E2 autoantibodies that have the ability to interfere with the
inhibitory activity of serpin E2 might cause a different outcome in
rheumatoid arthritis (RA). Numbers in parentheses are reference
numbers. uPA  urokinase plasminogen activator.
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influence cartilage destruction through the in vivo im-
pairment of the function of serpin E2. In the present
study at least, we showed that autoantibodies isolated
from the sera of RA patients impaired the inhibition of
uPA activity by serpin E2 in vitro and that high anti–
serpin E2 autoantibody levels correlated with high uPA
activity in vivo. Moreover, since serpin E2 is abundantly
present in atherosclerotic plaques (45) and since vascu-
lar changes are common in RA patients (49), we con-
clude that the anti–serpin E2 autoantibodies could also
play a role in the formation of the atherosclerotic
plaques. We are currently performing studies to address
this possibility. To our knowledge, this study is the first
to show a distinct effect of an autoantibody that might be
related to the pathogenesis of RA.
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a b s t r a c t
The aggressive phenotype of RA synovial ﬁbroblasts (RASF) is characterised by the increased expression
of matrix metalloproteinase (MMP)-1 as well as the small ubiquitin like modiﬁer (SUMO)-1 and
decreased expression of SUMO-speciﬁc protease SENP1. Since we showed an increased activity of ace-
tyltransferases in this autoimmune disease, we wanted to analyze whether this affects the expression of
MMP-1 and can be reversed by the reconstitution of SENP1.
In RASF, the acetylation of histone H4 was signiﬁcantly increased in the distal region of the MMP-1
promoter by 274  36% compared to OASF. Most interestingly, overexpression of SENP1 in RASF
decreased acetylation speciﬁcally in this region by 51  0.5% and globally by 73  11%. Furthermore, the
overexpression of SENP1 resulted in a downregulation of MMP-1 at both the mRNA (58  7%) and protein
levels (28  6%), signiﬁcantly reduced the invasiveness of RASF (from 34  9% to 2  2%) and led to an
accumulation of histone deacetylase 4 (HDAC4) on the MMP-1 promoter (197  36%). Interestingly,
SENP1 failed to modulate the expression of MMP-1 in the cells silenced for HDAC4. This is the ﬁrst study
linking the SUMOylation pathway and the production of MMP-1 to an epigenetic control mechanism
mediated through histone acetylation which has a functional consequence for the invasiveness of RASF.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
characterised by persistent inﬂammatory processes in the joints
resulting in a progressive articular destruction associated with the
loss of joint function and disability [1,2]. RA synovial ﬁbroblasts
(RASF) are intrinsically activated and therefore invade into cartilage
by excessive expression of matrix degrading enzymes such as
matrix metalloproteinases (MMPs) MMP-1, 3, 9, 10 and 13 [3e7].
MMP-1 is one of the most important MMPs since it is responsible
for cartilage destruction by cleaving collagen type II.
Recently, our group could show that in RA synovial tissues the
balance of activity of histone acetyltransferases (HATs) and histone
deacetylases (HDACs) is strongly shifted towardshistoneacetylation
[8], which is associated with increased transcription rates [9,10].
This posttranslational modiﬁcation of histones belongs to epige-
netic modiﬁcations regulating gene expression and offers us new
mechanism for therapeutic strategies. Another posttranslational
modiﬁcation described in RA is SUMOylation [11,12].We could show
that RASF have intrinsically high levels of small ubiquitin like
modiﬁer (SUMO)1 paralleled by decreased levels of its speciﬁc
protease (SENP1) which renders them apoptosis-resistant.
Whereas posttranslational modiﬁcations such as acetylation/
deacetylation directly inﬂuence gene transcription, SUMO-1 can
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inﬂuence the properties of its substrates such as stability, locali-
zation, interactionwith other proteins and activity [13e15]. Histone
deacetylase 4 (HDAC4) is known to be modiﬁed by SUMO-1 and
this is thought to modulate its activity as a negative regulator of
transcription [16]. There is, however, uncertainty regarding the
inﬂuence of SUMOylation on the activity of HDAC4. Kirsh et al.
reported that a SUMOylation-deﬁcient mutant of HDAC4 shows
only a slightly impaired ability to repress the transcription while
the nuclear transport of HDAC4 results from the modiﬁcation by
SUMO-1 [16]. This suggests that sumoylation of HDAC4 could
rather contribute to the change in the localization of HDAC4 than
inﬂuence the activity directly.
Since SUMO-1 is a modiﬁer of a wide range of transcription and
epigenetic factors, we studied here to which extent the activated
phenotype of RASF characterised by excessive production of MMP-
1 can be modiﬁed by epigenetic changes driven by desumoylation.
This is the ﬁrst study linking SUMOylation and the production of
MMP-1 to an epigenetic control mechanism mediated through
histone acetylation, and therefore, it supports the idea that epige-
netic modulations are involved in RA [17].
2. Materials and methods
2.1. Cells and patients
Synovial ﬁbroblasts were obtained from RA (n ¼ 8) and OA
patients (n ¼ 3) undergoing joint replacement surgery and grown
in DMEM with 10% FCS until passages 4e6 as described [18]. All RA
patients fulﬁlled the American College of Rheumatology criteria for
RA [19].
2.2. Expression vectors, siRNA, and transfection
A GFP-tagged SENP1 expression vector (SENP1-pEGF-C1) was
generatedby subcloningSENP1 intopEGF-C1 asdescribedpreviously
[12]. HDAC4 siGENOME SMARTpool was purchased from Dharma-
con, Lausanne, Switzerland and siRNA HDAC4 from Santa Cruz,
Heidelberg, Germany. The mock vector pEGF-C1 or mismatch oligo-
nucleotides (Qiagen, Hombrechtikon, Switzerland) were used as
controls. Transfection of the cellswith SENP1andHDAC4 siRNAwere
performed by AMAXA nucleofection as described previously [20].
2.3. Chromatin immunoprecipitation
In a typical experiment, 0.5 million of SF were harvested,
chromatin was crosslinked with 1% formaldehyde for 10 min and
the reaction was quenched by adding glycine. Cells were washed
twice, snap frozen and stored at 80 C or immediately used.
Chromatin sonication was performed on ice in SDS lysis buffer
containing protease inhibitors (1 protease inhibitors cocktail,
Roche, Basel, Switzerland), 5 mM sodium butyrate (Sigma, Buchs
SG, Switzerland) and 2.5 mM trichostatin A (TSA, Sigma) using
Bandelin sonopuls UW 2070 sonicator and a program of 4 cycles of
10 s at 57% power. The efﬁciency of the sonication of the chromatin
was analysed by gel electophoresis. 10% of the sample were kept as
input. Chromatin was diluted in ChIP dilution buffer and pre-
cleaned by incubation with normal rabbit serum and pre-blocked
Protein A agarose beads (Upstate/Millipore, Zug, Switzerland) for at
least 2 h. Chromatin immunoprecipitation was performed by
overnight incubation with anti-acetyl H4 antibodies, rabbit anti-
HDAC4 antibodies (Santa Cruz) or isotype IgG as a negative control
and followed by at least 4 h incubation with Protein A agarose
beads. Subsequently, immunoprecipitates were washed with
buffers containing protease inhibitors and sodium butyrate and
incubated for 20 min with the elution buffer containing proteinase
K. Reverse crosslinking was performed overnight at 64 C and the
DNA was puriﬁed using the QIAquick gel extraction kit (Qiagen).
2.4. RNA extraction
Total RNA was isolated and converted into cDNA and gene
expression was quantiﬁed by Real-time PCR as described [20,21].
2.5. Real-time polymerase chain reaction
2.5.1. Quantiﬁcation of mRNA
Expression of MMP-1 was assessed using self designed previ-
ously published primers and probe [22] and HDAC4 mRNA was
quantiﬁed by Real-time PCR using SybrGreen primers: fwd 50- TGT
ACGACG CCA AAGATGAC -30, rev 50- CGG TTC AGA AGC TGT TTT CC
-30. To conﬁrm speciﬁc ampliﬁcation by SybrGreen PCR, dissocia-
tion curve analysis was performed and water controls were
included for the primer pair and NRT controls were analysed for all
samples. The amounts of loaded cDNA were normalized using
a predeveloped 18S assay (PE Applied Biosystems). Differential
gene expression was calculated with the threshold cycle (Ct) and
the comparative Ct method for relative quantiﬁcation. All reactions
were performed in duplicates.
2.5.2. Quantiﬁcation of ChIP
Immunoprecipitated promoter fragments were quantiﬁed by
Real-time PCR using SybrGreen primers. The primer sequences
used are as follows: for MMP-1 ChIP1 fwd 50- TGG GAT ATT GGA
GCAGCA AG -30, rev 50- AGC TGT GCATAC TGG CCT TT -30; forMMP-
1 ChIP2 fwd 50- TAA GGG AAG CCA TGG TGC TA -30, rev 50- AGG TTC
CCT TCT GCC TTT CT -30; for MMP-1 ChIP3 fwd 50- TGA CTG GGA
AGT GGA AAC CT -30, rev 50- GCC TGC AAT GGT GAG TCAT -3. To
conﬁrm speciﬁc ampliﬁcation by SybrGreen PCR, dissociation curve
analysis was performed and water controls were included for each
primer pair. The amounts of immunoprecipitated fragments of
genomic DNA were normalized to the input DNA. Differential
immunoprecipitation of promoter fragments was calculated with
the threshold cycle (Ct) and the comparative Ct method for relative
quantiﬁcation. All reactions were performed in duplicates.
2.6. Immunoﬂuorescence
Immediately after transfection, cells were plated on chamber
slides and incubated for 48 h. Cells were washed with PBS. Fixation
was performed using 4% paraformaldehyde in PBS for 10 min at
room temperature. Cells were washed with PBS and permeabilized
with freshly prepared 0.1% triton X-100 (Beucher & Hobein, AG,
Zurich, Switzerland) in PBS for 10 min at room temperature. All the
solutions used in the following steps contained 0.1% triton X-100.
Cells were blocked for 1 h using 8% BSA in PBS and incubated
overnight with rabbit anti-acetyl H4 antibodies (Upstate/Millipore)
or an IgG isotype in 3% BSA in PBS. Cells werewashed and incubated
with Cy3 conjugated goat anti-rabbit antibodies (Jackson
ImmunoResearch). After washing cells were mounted. The detec-
tion of SENP1-pEGF-C1 and the acetylated histone H4 was per-
formed by ﬂuorescence microscopy.
2.7. Flow cytometry analysis (FACS)
Cells were permeabilised with 0.4% triton X-100 and incubated
with rabbit anti-acetyl H4 (Upstate/Millipore) antibodies and fol-
lowed by incubation with R-Phycoerythrin-labeled donkey anti-
rabbit antibodies (Jackson ImmunoResearch). Unbound antibodies
were removed by two washing steps. In control experiments
primary antibodies were replaced by a mouse IgG isotype in the
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45
same concentration. Measurements were performed using 10.000
cells per sample at ‘‘low-ﬂow’’ modus using FACSCalibur (BD
Biosciences, Allschwil Switzerland).
2.8. Acid extraction of histones
Following transfection, cells splited into two portions and the
ﬁrst portion was subjected to acid extraction of histones, while
second portion was lysed in Lemmli buffer and used to assess the
efﬁciency of the transfection. The acid extraction was performed as
previously described [23]. Brieﬂy, nuclear extractswere prepared by
cell lysis in cold hypotonic lysis buffer (10mM TriseCl pH 8.0, 1 mM
KCl, 1.5 mMMgCl2, 1 mM DTT, 1 mM PMSF, containing 1 protease
inhibitors cocktail (Roche),1.25mg/ml sodiumbutyrate (Sigma) and
2 mMTSA (Sigma)). The nuclei were resuspended in 0.4 NH2SO4 and
incubated on a rotator at 4 C for 1 h. Next, histones were precipi-
tated overnight by 33% trichloroacetic acid. The histone pellet was
washed with ice-cold acetone and resuspended in distilled water.
2.9. Western blot
Following transfection, lysates were suspended in 2 concen-
trated Lemmli buffer (100 mM Tris HCl [pH 6.8], 40% glycerol, 10%
sodium dodecyl sulfate [SDS], 0.7 M b-mercaptoethanol, and
0.0005% bromphenol blue) and separated by SDS-PAGE under
reducing conditions and transferred to nitrocellulose membranes
as previously described [18]. Membranes were blocked with 5%
milk for 1 h at RT and then incubated overnight with rabbit anti-
acetylated histone H4 (Upstate/Millipore), rabbit anti-SENP1
(Chemicon, Asperg, Germany) or mouse anti-MMP-1 (R&D
Systems). As secondary reagents, HRP-conjugated goat anti-rabbit
antibodies (Jackson ImmunoResearch, Magden, Switzerland) or
HRP-conjugated rabbit anti-mouse IgG antibodies (DAKO, Baar,
Switzerland) were used, and signals were visualized with an
enhanced chemiluminescence system (Amersham Biosciences,
Otelﬁngen, Switzerland). For normalization, membranes were
stripped and probed with mouse anti-human a-tubulin (Sigma),
mouse anti-paxillin antibodies (Neomarkers, Basel, Switzerland) or
rabbit anti-histone H4 (Upstate/Millipore). Evaluation of the
expression of speciﬁc proteins was performed using the Alpha
imager Software system (Alpha Innotech, San Leandro, CA) via pixel
quantiﬁcation of the electronic image.
2.10. Cell invasion assay
Investigation of synovial ﬁbroblast invasion in vitro was per-
formed using the recently established matrix associated trans-
epithelial resistance invasion (MATRIN) assay as described [24].
This is a highly sensitive electrophysiological technique that is
based on the measurement of the electrical resistance of a mono-
layer of the C7 subclone of MadineDarby canine kidney cells
(MDCK-C7). MDCK-C7 cells were grown in MEM on the back of
a 0.4-mm ﬁlter cup. Pooled RASF from two patients were transfected
with SENP1 (SENP1-pEGF-C1) or the empty vector (pEGFP-C1), and
5  105 cells were seeded onto a collagen matrix consisting of 97%
type I collagen and 3% type III collagen that was used to coat the top
of the ﬁlter cup. The resistance across this monolayer was
measured with a STX2 electrode. The invasion was recorded 12, 19
and 23 h after seeding the cells. Measurement for all cells was
performed in triplicates.
2.11. Statistical analysis
All data are expressed as mean  SEM. ManneWhitney U-test
was used for comparison between two groups of data. p values
lower or equal to 5% were considered statistically signiﬁcant
(p  0.05).
3. Results
3.1. RASF have higher intrinsic levels of acetylated histone
H4 in the promoter of MMP-1 than OASF
Sincewe could show that the acetylation of histones is increased
in RA [8] we investigated whether there is hyperacetylation of
histones in the promoter of MMP-1 in RASF compared to OASF
contributing to its overexpression in RA. We performed chromatin
immunoprecipitation in RASF and OASF using anti-acetyl H4 anti-
bodies and analysed 3 different regions spread along the promoter
of MMP-1. Most interestingly, we found that in the upstream region
1524 to1464 from the transcription starting point of theMMP-1
promoter, the levels of acetylation of histone H4 were signiﬁcantly
increased in RASF when compared with OASF (percent change
274  SEM 36%, n ¼ 3, p  0.05, Fig. 1A). The levels of acetylated
histone H4 in the 552 to 488 upstream region from the tran-
scription starting point were slightly lower in RA when compared
to OA (22  9%, n ¼ 3, p  0.05). There was no difference in acet-
ylation of histones in the region 179 to 130 upstream from the
transcription starting point. Therefore, we hypothesised that
hyperacetylation of the MMP-1 promoter could result in an
intrinsically upregulated production of MMP-1 in RASF.
3.2. SENP1 overexpression leads to a decrease in acetylation of
histone H4 in the promoter of MMP-1
RASF are characterised by increased SUMOylation due to an
upregulation of SUMO-1 and the downregulation of SENP1. To
reverse this phenotype we overexpressed SENP1 in RASF using an
expression construct of SENP1 (SENP1-pEGF-C1) or the empty
vector (mock transfected, pEGF-C1) and analysed the acetylation
status of the MMP-1 promoter. We found that the levels of acety-
lated histone H4 in the region at 1524 to 1464 bp from the
transcription starting point were signiﬁcantly downregulated by
the overexpression of SENP1 by 51  0.5% (n ¼ 3, p  0.05, Fig. 1B).
The levels of acetylatedhistoneH4 in the twoother analysed regions
were not signiﬁcantly different in cells overexpressing SENP1.
3.3. Desumoylation decreases the global levels of acetylated
histone H4
Since SENP1 overexpression decreased the acetylation level in
the promoter of MMP-1 we were interested whether the decrease
in acetylation of histones is also a global phenomenon. Thus, we
compared the global levels of acetylated histone H4 in the cells
transfected with SENP1-pEGF-C1 or the mock vector. As visualized
by immunoﬂuorescence, RASF transfected with SENP1-pEGF-C1
revealed lower global levels of acetylated histone H4 when
compared both to nontransfected or GFP transfected cells (n ¼ 3,
Fig. 2A). Using ﬂow cytometry analysis we could further conﬁrm
that the global levels of H4-acetylationwere signiﬁcantly decreased
by 73  SEM 11% when compared to pEGF-C1 cells (n ¼ 3, p < 0.05,
Fig. 2B). In addition, using Western blot we could conﬁrm that the
3-fold overexpression of SENP1 (Fig. 2C) leads to a decrease in
acetylation of histone H4 (by 51  SEM 4%, Fig. 2D).
3.4. Overexpression of SENP1 results in a downregulation
of MMP-1 in RASF
After we observed decreased acetylation of histones in the
MMP-1 promoter in RASF overexpressing SENP1, we wanted to
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analyze whether it resulted in a repression of MMP-1 transcription.
Indeed, the overexpression of SENP1 downregulated the expression
ofMMP-1mRNA by (mean SEM) 58 7% (n¼ 5, p 0.05, Fig. 3A).
Furthermore, the protein levels of MMP-1 were signiﬁcantly
decreased by 28  6% (n ¼ 3, p  0.05) in RASF overexpressing
SENP1 compared to mock transfected cells (Fig. 3B).
3.5. Overexpression of SENP1 in RASF results in a functionally
reduced invasiveness
Next, since we observed that the overexpression of SENP1
downregulated the expression of MMP-1 in RASF, we wanted to
investigate whether therefore also the invasiveness of these cells
decreased. Indeed, using an in vitro functional invasion assay, we
could observe that RASF transfected with SENP1 for 23 h were
signiﬁcantly less invasive (2 2% decrease in TEER) compared to the
mock transfected cells (34  9% decrease in TEER, p  0.05, Fig. 3C
and D). At the earlier time points (12 and 19 h after transfection) we
could not observe a signiﬁcant difference in the invasiveness of
SENP1 overexpressing RASF compared to the control cells (Fig. 3D).
In conclusion, we could show that the overexpression of SENP1 in
RASF not only alters the expression of MMP-1 but also functionally
interferes with the invasive phenotype of RASF.
3.6. Overexpression of SENP1 leads to an accumulation of histone
deacetylase HDAC4 on the MMP-1 promoter
Since SENP1 overexpression results in a decrease in acetylation
of histones at the MMP-1 promoter, we were interested whether
this is due to the counterplaying histone deacetylases. Since HDAC4
is a substrate for sumoylation and this modiﬁcation is connected
with a change of localization of HDAC4, we hypothesised that the
overexpression of SENP1 could mediate histone deacetylation
through localizing HDAC4 to speciﬁc regions of chromatin. To
investigate whether this is the case, we performed chromatin
immunoprecipitation using anti-HDAC4 antibodies in RASF trans-
fected with the SENP1 expression vector or with the mock control.
Next, Real-time PCR for the different regions of the MMP-1
promoter was performed. The level of HDAC4 in the region at
1524 to 1464 bp from the transcription starting point was
signiﬁcantly increased in RASF overexpressing SENP1 when
compared to the mock transfected cells by (mean  SEM)
197  36% (n ¼ 3, p  0.05, Fig. 4A). There was no signiﬁcant
change in HDAC4 detected in the two other analysed regions.
Therefore, the overexpression of SENP1 resulted in a signiﬁcant
increase of HDAC4 localized to the MMP-1 promoter and to the
signiﬁcantly decreased acetylation of histone 4 in the same region
of the promoter.
3.7. SENP1 requires HDAC4 for downregulation
of MMP-1 expression
Since SENP1 overexpression lead to an increase in the localiza-
tion of HDAC4 and at the same time to a decrease of histone acet-
ylation in the promoter of MMP-1, we were interested whether
HDAC4 mediates the downregulation of MMP-1 expression in
SENP1 overexpressing cells. Therefore, we silenced the expression
of HDAC4 and next overexpressed SENP1. As expected, SENP1
Fig. 1. Acetylation of histone H4 in the promoter of MMP-1. Chromatin immunoprecipitation assay showing acetylated histone H4 in the promoter regions of MMP-1 (179 to
130 bp, 552 to488 bp and 1524 to 1464 bp regions upstream from the transcription staring point). (A) Baseline levels of acetylated histone H4 in three regions of the MMP-1
promoter in RASF compared to OASF (n ¼ 3 each). The levels of acetylated histone H4 are given in % of input  SEM and shown in white and black bars respectively. IgG serves as
a negative control (paned bars). (B) Levels of acetylated histone H4 in three regions of the MMP-1 promoter in RASF following the overexpression of SENP1. The levels of acetylated
histone H4 in mock (n ¼ 3) and SENP1 transfected RASF (n ¼ 3) are given in % of input  SEM and shown in white and black bars respectively. IgG serves as a negative control
(paned bars).
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overexpression in cells transfected with control siRNA lead to
a decreased MMP-1 mRNA production. Most interestingly, in the
cells silenced for HDAC4 and next transfectedwith SENP1 the levels
of MMP-1 mRNA were signiﬁcantly higher than in the cells trans-
fected with SENP1 but expressing HDAC4 (percent change
190 SEM 20%, n ¼ 3, p  0.05, Fig. 4B). Also at the protein level, in
the cells silenced for the expression of HDAC4 and next transfected
with SENP1 we could not observe a downregulation of MMP-1 in
contrast to the cells transfected with control siRNA and next
SENP1-pEGF-C1 (percent difference 156  SEM 9%, Fig. 4C).
Therefore, SENP1 requires HDAC4 for the downregulation of MMP-
1 expression.
4. Discussion
We could show here for the ﬁrst time that the MMP-1
promoter is intrinsically hyperacetylated in RASF when compared
to OASF. Most interestingly, the increased cleavage of the intrin-
sically overexpressed SUMO-1 in RASF by SENP1 re-established
the acetylation pattern in the MMP-1 promoter by deacetylation
of histones in the distal fragment of the MMP-1 promoter.
Furthermore, the overexpression of SENP1 led to a decrease in the
production of MMP-1 and functionally interfered with the inva-
sive phenotype of RASF. The transcriptional repression of MMP-1
was mediated by an epigenetic mechanism and depended on
HDAC4.
It has been described by Huber et al. that in RA synovial tissues
the balance of HAT/HDAC activity is strongly shifted towards
histone acetylation [8]. In addition, it has been shown that several
HDAC inhibitors had rather beneﬁcial effects in the animal models,
where they were shown to improve joint swelling, synovial
inﬂammation, bone and cartilage destruction, downregulated the
production of VEGF, blocked angiogenesis and promoted cell cycle
arrest and apoptosis [25e28]. These reports suggest that HDACs
could be misplaced in the subcellular compartments for example
being localized aberrantly to speciﬁc promoter sites, and thereby
contribute further to the pathogenesis of RA. Therefore, it should be
carefully considered whether inhibition of HDACs or rather their
redirection to a proper localization is more feasible for the treat-
ment of RA.
Fig. 2. Modulation of global acetylation of histone H4 in RASF by overexpression of SENP1. (A) Immunoﬂuorescent staining of acetylated histone H4 (red) in RASF transfected with
SENP1epEGF-C1 (green, upper panel) or mock pEGF-C1 vector (green, lower panel) (B) Levels of acetylated histone H4 in control cells transfected with the empty vector pEGF-C1
(n ¼ 3, white bar) and SENP1 transfected cells (n ¼ 3, black bars) measured by FACS are shown as mean ﬂuorescence intensity  SEM. Representative FACS picture for acetylated
histone H4 in SENP1epEGF-C1 and pEGF-C1 transfected cells is shown in the inset. (C) Representative Western blot showing levels of SENP1 in mock-and SENP1-transfected RASF.
As internal control a-tubuline was used. The levels of SENP1 expression in mock- (white bar) and SENP1-transfected RASF (black bar) were quantiﬁed using densitometric analysis
software and normalized against a-tubulin. The values from 3 experiments are shown as mean ratio of densospot units  SEM. (D) Representative Western blot showing levels of
acetylated histone H4 in mock-and SENP1-transfected RASF (upper panel). As internal control histone H4 was used (lower panel). The ratio of acetylated histone H4/histone H4 in
mock- (white bar) and SENP1-transfected RASF (black bar) were quantiﬁed using densitometric analysis software. The values from 3 experiments are shown as mean ratio of
densospot units  SEM.
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RASF play a crucial role in cartilage destruction byactive invasion
via producing MMPs [6]. Therefore, targeting of the intrinsically
activated RASF could lead to the development of new therapeutic
strategies for RA. We could previously show that RASF are charac-
terised by high expression levels of SUMO-1 and at the same time
low levels of SENP1 [12]. Here we demonstrate that reversing this
balance by overexpression of SENP1 leads to a decrease in the
invasiveness of RASF and downregulates the expression of MMP-1.
Most interestingly, this regulation is dependent on a transcription
inhibitor, HDAC4, since in cells silenced for HDAC4 the over-
expression of SENP1 failed to decrease the expression of MMP-1.
Furthermore,we could show that upon the overexpression of SENP1
in RASF, HDAC4, localized especially to the distal region of theMMP-
1 promoter. HDAC4 has been shown to bemodulated by SUMO-1 by
a SUMO ligase RanBP2 in the nuclear pore complex [16]. This
suggests that sumoylation of HDAC4 promotes nuclear transport of
themodiﬁedprotein. Such amechanismhas been shown for nuclear
translocation of the insulin gene regulator Pdx1 aswell as the tumor
suppressor Smad4 [29e31]. We show here that SENP1 over-
expression in the nucleus of RASF led further to the speciﬁc accu-
mulation of HDAC4 on the DNA. Furthermore, SENP1 driven
modulation of HDAC4 localization re-established the acetylation
pattern in theMMP-1 promoter in RASF bydeacetylation of histones
in the distal fragment of theMMP-1 promoter. This promoter region
contains predicted binding sites for acetyltransferases such as C/
EBPa andp300.Moreover, this promoter region contains a predicted
binding site for IRF-3, which was described to be superactivated in
RA synovial tissues [32], to be regulated byHDAC inhibitors [33] and
to interactwith PIASy, a SUMO ligase [34]. It needs to be investigated
whether IRF-3 regulates the transcription of MMP-1. On the
contrary, no signiﬁcant changes were observed in both acetylation
of histones and HDAC4 levels after the overexpression of SENP1 in
the AP-1 binding site proximal to the transcription starting point
(179 to 130 upstream from the transcription starting point) as
well as the region 552 to 488 upstream from the transcription
starting point to which no histone acetyltransferases have been
predicted to bind.
Most interestingly, we were able to show that the over-
expression of SENP1 leads to a decrease in the global acetylation of
chromatin. This is the ﬁrst study showing that interferencewith the
sumoylation pathway can decrease the invasiveness of RASF and
down-modulates the expression of MMP-1 via epigenetic changes
in the chromatin. We therefore propose that the sumoylation
pathway could be a promising target for therapy in RA, by inhib-
iting both the resistance to induced apoptosis and the invasiveness
of RASF mediated by MMP-1.
Fig. 3. Modulation of MMP-1 expression and invasiveness of RASF by overexpression of SENP1. (A) Levels of MMP-1 after transfection of RASF with SENP1. Levels of MMP-1 mRNA
in the control cells transfected with the empty vector pEGF-C1 were set as 100% (white bar) and respective values for SENP1 transfected cells (n ¼ 5, black bars) are shown as mean
fold change  SEM. Values were normalized for the expression of 18S. (B) Representative Western blot showing levels of MMP-1 expression in mock-and SENP1-transfected RASF
(upper panel). SENP1 in mock-and SENP1 transfected cells is shown in the middle panel. As internal control a-tubuline was used. The levels of MMP-1 expression in mock- (white
bar) and SENP1-transfected RASF (black bar) were quantiﬁed using densitometric analysis software and normalized against a-tubulin. The values from 3 experiments are shown as
mean ratio of densospot units for MMP-1/a-tubulin change  SEM. (C) Invasiveness of RASF transfected with mock vector pEGF-C1 (white bar) or SENP1 (black bar) shown as %
reduction of electrical resistance of a monolayer of MDCK-C7 cells. (D) Invasiveness of RASF transfected with mock vector pEGF-C1 or SENP1 shown as % of electrical resistance of
a monolayer of MDCK-C7 (TEER) cells at different time points, where the resistance at time 0 was set as 100%.
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4 Outlook
4.1 Autoantibodies
4.1.1 Anti-serpin E2 autoantibodies
In the first part of my PhD work I identified novel and functional autoantibodies
against serpin E2 in sera and synovial fluids of RA patients. The analysis of a
bigger cohort of sera which was performed in a follow up study in our laboratory
showed that the anti-serpin E2 autoantibodies are also present at high levels in
sera of healthy individuals. Since I could show that anti-serpin E2 autoantibodies
can abbrogate serpin E2 inhibitory activity towards uPA, most probably they have
a functional role in the physiological conditions. It would be interesting to analyze
whether healthy individuals with high and low serum levels of anti-serpin E2 differ
regarding for example predisposition to develop thrombosis, arthritis or cancer.
Furthermore, by immunohistochemistry, I could show that serpin E2 is overex-
pressed in the synovial tissues of RA patients. It remains unresolved what is the
level of serpin E2 activity in the synovium of RA patients. Even though serpin E2
is overexpressed, it might be inhibited by the anti-serpin E2 autoantibodies, which
are present at increased levels in the synovial fluids of patients with RA when com-
pared to OA. It also remains to be verified whether the increased levels of serpin
E2 drive the retention of the leukocytes specific for serpin E2 and/or their activa-
tion and therefore the increased production of serpin E2 specific autoantibodies.
Otherwise, the increased presence of anti-serpin E2 autoantibodies as a negative
regulator of serpin E2 could upregulate the expression of the latter. Whether the
binding of the specific autoantibodies to serpin E2 can drive the expression of
the antigen could be verified in vitro for example by incubating fibroblasts with
the isolated anti-serpin E2 autoantibodies alone or together with serpin E2. It
has been reported that recombinant human serpin E2 administrated in a rabbit
model of arthritis improved the symptoms [174]. To study the inhibitory effects of
anti-serpin E2 autoantibodies in an in vivo model, it would be interesting to verify
if administration of serpin E2 along with anti-serpin E2 autoantibodies isolated
from sera had similar effects. In the human circulation serpin E2 is expressed by
platelets [175]. Platelet serpin E2 was shown to have antithrombotic properties
53
CHAPTER 4. OUTLOOK
since it inhibits thrombin and is thought to be a key player in the thrombotic pro-
cess [175]. In this respect, it is possible that anti-serpin E2 autoantibodies could
play a role as a prothrombotic regulator. While in the PhD work I have shown that
the levels of of anti-serpin E2 autoantibodies correlate with the activity of another
protease inhibited by serpin E2, namely uPA, whether anti-serpin E2 autoanti-
bodies correlate with the activity of thrombin remains to be verified. A similar
approach to the one where the inhibition of uPA was studied could be used in
the case of thrombin. On the other hand, in the pathologic conditions, serpin E2
was found to be overexpressed in atherothrombotic lesions [175]. It is perhaps not
surprising that at the site of increased activity of thrombin its negative regulator
is present. Nevertheless, whether serpin E2 at this site is bound and inhibited by
the naturally occurring autoantibodies remains unverified. If so, even the strong
expression of serpin E2 observed in advanced lesions could be insufficient to inhibit
thrombin. In this view a naturally occurring anti-serpin E2 autoantibodies could
play a pathological role at the site of atherothrombotic lesions. It would be there-
fore interesting to verify whether the anti-serpin E2 autoantibodies are present at
the site of the atherothrombotic lesions and if they correlate with the activity of
thrombin and/or the size of the atherothrombotic plaque.
4.1.2 Other novel autoantibodies
Except from serpin E2, using the SEREX technique I identified four other poten-
tial autoantigens, namely: CTGF, GLOI, NRG1 and PTTG1IP. It needs further
investigation whether there are autoantibodies against these molecules present in
more individuals, and whether they are connected with RA. The potential autore-
activity of CTGF is of interest since CTGF is a key player in another autoimmune
disease, systemic sclerosis (SSc). SSc is an autoimmune disorder in which patho-
logic features include progressive tissue fibrosis and widespread vascular involve-
ment. CTGF is overexpressed in SSc and is believed to be a primary mediator of
chronic fibrosis [176, 177]. It would be therefore interesting to verify the existence
of anti-CTGF autoantibodies not only in RA, but also in the circulation of pa-
tients with SSc as well as other autoimmune diseases. Another interesting possible
autoantigen identified in the study was glyoxalase I (GLOI). GLOI is an enzyme
involved in the detoxification of a metabolic by-product, methylglyoxal. Targeting
GLOI appears promising in the treatment for cancer since the methylglyoxal is
preferentially toxic to the cells proliferating at a high rate [178, 179]. Little how-
ever is known about GLOI in RA, except that GLOI mRNA is increased twice
in RA compared to OA tissues [180]. It would be therefore interesting to verify
the autoantibodies against GLOI in RA. It might be of interest whether possible
anti-GLOI autoantibodies could interfere with the activity of GLOI in a similar
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manner like anti-serpin E2 autoantibodies block their antigen activity. If anti-
GLOI antibodies indeed had blocking properties, it could be hypothesized that
they could play a role in the regulation of cell proliferation. Furthermore, such
an inhibitor could be of potential value as an inhibitor of cancer development. It
could be therefore interesting to study whether there exists any relation between
the presence of anti-GLOI antibodies and the risk of developing cancer. A next
potential novel autoantibodies identified in my study is anti-NRG1. Interestingly,
NRG1 has an Ig-like domain. It is intriguing whether autoimmunity could rise
to such a protein especially in the RF positive patients due to the recognition of
the Ig-like domain by the RF. On the other hand, the identification of NRG1 as
a potential autoantigen using the SEREX technique might be simply an artifact,
since it is possible that the anti-IgG antibodies used for detection of the autoan-
tibodies bound directly the Ig-like domain of NRG1. Due to the same reason,
even if there exist anti-NRG1 autoantibodies, their further study would be very
challenging. Pituitary tumor-transforming gene 1 (PTTG1) interacting protein
(PTTG1IP) was another possible autoantigen identified using the SEREX tech-
nique. PTTG1IP was shown to have both pro- and anti-tumorigenic properties
[181]. Up to date there are no reports linking PTTG1IP to autoimmunity. Never-
theless, PTTG1IP has been suggested to play a role in osteoblast differentiation,
a process not efficient in RA [182]. It would be therefore interesting to investigate
the expression and function of PTTG1IP in cartilage and synovium in the RA
joint. It is possible that PTTG1IP could increase the invasiveness of the resident
cells in the synovial tissue since it was reported to play such a role in breast cancer
cells. Furthermore, since PTTG1IP has been suggested to play a role in osteoblast
differentiation it might be interesting to verify whether the autoantibodies against
PTTG1IP interfere with osteoblast differentiation and attempted repair processes
in the affected joints in RA.
4.2 SENP1 study
In the second part of my PhD work I showed that the expression of MMP-1 is
regulated by SENP1. I showed that SENP1 overexpression leads to the local-
ization of HDAC4 and deacetylation of histone H4 in the promoter of MMP-1.
Even though I could show that in the cells silenced for HDAC4 SENP1 overex-
pression failed to downregulate MMP-1, it could be also investigated whether in
those cells the acetylation of MMP-1 promoter remains unchanged upon SENP1
overexpression. Even though it is clear that SENP1 requires HDAC4 for regulat-
ing expression of MMP-1, the exact mechanism remains unknown. It is of high
interest to provide such a mechanism since the inhibition of HDACs proved bene-
ficial in several animal models of RA [34, 35] even though in RA synovial tissues
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the balance of HAT/HDAC activity is strongly shifted towards histone acetylation
[33]. This discrepancy could be explained if HDACs were localized aberrantly to
specific promoter sites, and thereby contributed further to the pathogenesis of RA.
If that was the case, the possibility of redirection of HDACs to proper sites would
be very desired. Since sumoylation of HDAC4 can affect its localization it is pos-
sible that SENP1 driven desumoylation of HDAC4 would change the location of
HDAC4. This could happen on the cytoplasm-nucleus or intranuclear level and, as
a result, HDAC4 could be recruited to particular promoter sites. The more prob-
able of this two hypothesis is the first one since the deacetylation of histone H4
driven by SENP1 overexpression was observed not only on the promoter of MMP-1
but also globally. It could be addressed by Western blot analysis of HDAC4 in
the cytoplasmic and nuclear fractions in the cells transfected with SENP1. The
intranuclear changes in the localization of HDAC4 could be studied using Chip
on Chip technique. On the other hand, SENP1 overexpression could lead to an
increase in the total levels of HDAC4. This could be accomplished for example
via SP1/SP3 transcription factors, since they are described stimulators of HDAC4
transcription and they are active in their desumoylated form [183, 184, 185]. An
increase in HDAC4 expression could result in its increased binding to the pro-
moter of MMP-1 while a decrease in the total acetylated histone H4 might be
observed. It is also possible that sumoylation/desumoylation of HDAC4 influences
its interactions with transctription regulators. It would be therefore interesting to
compare the transcription factors interacting with the wild type and the sumoy-
lation mutant of HDAC4. This could be addressed using the yeast two hybrid
system. Another interesting point worth of studying in the future is the novel
regulatory region identified in the promoter of MMP-1. The acetylation of his-
tones in the region -1524 - -1464 upstream from the transcription site was different
in RASF and OASF and a decrease in the acetylation of H4 in this region was
paralleled by decreased levels of MMP1 expression. This promoter region was also
identified as HDAC4 binding site. Also other transcription factors are predicted to
bind to this region (STAT5A, C/EBPα, p300, GATA1, IRF-3, MZF-1, BTEB3).
It would be interesting to study this promoter region in more detail, for example
if it is necessary for the upregulation of MMP-1 by proinflamatory cytokines such
as TNFα. It has recently been reported that HDAC4 regulates the expression of
another collagenase, MMP-13 [186]. It might be suggested that SENP1 downreg-
ulated also MMP-13 (via HDAC4), since the overexpression of SENP1 decreased
the invasiveness of RASF much stronger then expected given the 30% change in
the expression of MMP-1. Furthermore, it could be investigated whether other
classes of MMPs are also regulated in a similar manner.
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Corrigendum
The following corrigendum to the article entitled ’Functional autoantibodies against
serpin E2 in rheumatoid arthritis characterizing novel anti-serpin E2 autoantibod-
ies present in RA’ Arthritis Rheum. 2010 Jan;62(1):93-104 will be sent together
with an addendum to the journal.
We published an article in Arthritis Rheum. 2010 Jan;62(1):93-104. entitled
Functional autoantibodies against serpin E2 in rheumatoid arthritis characterizing
novel anti-serpin E2 autoantibodies present in RA. We regret that in the Figure 3B
a wrong data set for the concentrations of anti-serpine2 autoantibodies in sera was
presented. The corected data are shown in Figure 1 corrigendum. We apologize
for any problems arising from this error.
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Figure 1 corrigendum : Comparison of published vs. corrected values of the levels
of anti-serpin E2 autoantibodies in sera. Levels of autoan-
tibodies reactive with rh serpin E2 in sera published as
Figure 3A in the manuscript (A) and corrected (B). Dots
represent values obtained for each individual and the mean
of total samples in each group is indicated with a black
bar. The red dots represent positive individuals. P values
were calculated using the Student T Test and p≤0.05 con-
sidered significant are indicated. The published and the
corrected values are summarized in a table (C). The mean
levels of anti-serpin E2 autoantibodies detected by ELISA
in sera are presented in the left panel. The percentage of
sera positive for anti-serpin E2 autoantibodies is given in
the right panel. (AU = arbitrary units). The values pub-
lished in the manuscript are presented in the first column
and the corrected values in bold in the second column in
both pannels.
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RT-PCR reverse transcription PCR
SCID severe combined immunodeficiency
SD standard deviation
SDS sodium dodecyl sulphate
SEM standard error of the mean
SENP1 sentrin/sumo specific protease
SEREX serological analysis of cDNA expression library
siRNA small interfering RNA
Serpin E2 serine protease inhibitor E2
SUMO-1 small ubiquitin-like modifier
TGFβ transforming growth factor β
Th T helper cell
TIMP tissue inhibitor of metalloproteinases
TLR toll-like receptor
TNFα tumor necrosis factor α
TNFRI TNF receptor I
tPA tissue plasminogen activator
TRAIL TNF-related apoptosis-inducing ligand
Treg T regulatory cell
TSA trichostatin A
uPA urokinase-type plasminogen activator
uPAR uPA receptor
VIM vimentin
79

Curriculum vitae
Surname: MACIEJEWSKA-RODRIGUES
First Name: Hanna
Date of Birth: 19th September 1981
Birthplace: Poland
Education:
1996-2000 Highschool, 1st Liceum of Gdan´sk, Gdan´sk, Poland
2000-2005 Master in Biology, University of Gdan´sk, Gdan´sk, Poland
2005-2011 Dr. sc. nat., Universita¨t Zu¨rich, Zu¨rich, Switzerland
Publications:
Original peer reviewed publications:
Hemmatazad H, Maciejewska Rodrigues H, Maurer B, Brentano F, Pileckyte
M, Distler J H, Gay R E, Michel B A, Gay S, Huber L C, Distler O and Ju¨ngel A
(2009) Histone deacetylase 7 - A potential target for the anti-fibrotic treatment of
systemic sclerosis. Arthritis Rheum. 60, 1519-1529
Maciejewska-Rodrigues H, Al-Shamisi M, Hemmatazad H, Ospelt C, Bouton
M C, Ja¨ger D, Cope A P, Charles P, Plant D, Distler J H, Gay R E, Michel B
A, Knuth A, Neidhart M, Gay S and Ju¨ngel A (2010) Functional autoantibodies
against serpin E2 in rheumatoid arthritis. Arthritis Rheum. 62, 93-104
Maciejewska-Rodrigues H, Karouzakis E, Hemmatazad H, Gay RE, Gay S,
Michel BA, Pap T, Ju¨ngel A (2010) Epigenetics and rheumatoid arthritis: The
role of SENP1 in the regulation of MMP-1 expression. Journal of Autoimmunity.
35, 15-22
Ospelt C, Mertens J, Ju¨ngel A, Brentano F, Maciejewska-Rodrigues H, Huber
L, Hemmatazad H, Wu¨est T, Gay RE, Gay S, Renner C and Bauer S (2010)
Fibroblast activation protein and dipeptidyl peptidase IV protect cartilage against
invasion by synovial fibroblasts. Arthritis Rheum. 62, 1224-35
81
Bibliography
Review papers:
Ju¨ngel A. andMaciejewska H (2007) Notes from the 6th Global Arthritis Reasearch
Network (GARN) meeting. Session 3. MskReport
Maciejewska-Rodrigues H, Ju¨ngel A, Gay R E, Gay S (2009) Review: Innate
immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol.
Nov;47(1):12-8
Book chapters:
Maciejewska-Rodrigues H, Ju¨ngel A, Gay S (2010) Handbook of Epigenetics:
The New Molecular and Medical Genetics. The role of epigenetics in immune
disorders. Elsevier, ISBN 13: 978-0-12-375709-8
82
